aspirin has been researched along with Breast Cancer in 230 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prediagnostic aspirin use was not found to be associated with lower breast cancer-specific mortality (HR, 0." | 9.22 | Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Barron, TI; Black, A; Bradley, MC; Freedman, AN, 2016) |
| "Aspirin (ASA) use has been associated with improved breast cancer survival in several prospective studies." | 9.19 | Aspirin intake and breast cancer survival - a nation-wide study using prospectively recorded data in Sweden. ( Adami, HO; Andersson, TM; Askling, J; Holm, J; Holmes, MD; Lundholm, C; Olsson, H; Pawitan, Y; Smedby, KE, 2014) |
| " We undertook a prospective study to determine the influence of a 45-day course of aspirin therapy on circulating and intraplatelet levels of selected proangiogenic (vascular endothelial growth factor [VEGF]) and antiangiogenic (thrombospondin-1 [TSP-1]) proteins, and platelet protein release in women diagnosed with breast cancer who were receiving tamoxifen therapy." | 9.17 | Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. ( Holmes, CE; Jasielec, J; Levis, JE; Muss, HB; Skelly, J, 2013) |
| "The Women's Health Study trial previously reported no overall effect of low-dose aspirin (100 mg every other day) on invasive breast cancer over an average of 10 years of treatment." | 9.13 | Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. ( Buring, JE; Cook, NR; Lee, IM; Manson, JE; Zhang, SM, 2008) |
| "VEGF and endostatin concentrations were measured with a quantitative immunoassay before and after 1 to 5 weeks of treatment in 30 women with breast cancer treated with either tamoxifen (n = 14) or aromatase inhibitors (n = 16)." | 9.13 | Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. ( Holmes, CE; Howard, AB; Huang, JC; Muss, HB; Pace, TR, 2008) |
| "Some evidence shows that aspirin can reduce the morbidity and mortality of different cancers, including breast cancer." | 9.12 | Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019. ( Guo, C; Han, T; Jiang, Y; Ma, S; Qu, G; Sun, C; Sun, Y; Zhang, H; Zhou, Q, 2021) |
| "The purpose of this study is to investigate whether aspirin improves the prognosis of breast cancer patients by meta analysis." | 9.12 | Effect of aspirin use on survival benefits of breast cancer patients: A meta-analysis. ( Liu, A; Liu, J; Wu, X; Yang, M; Zheng, F, 2021) |
| "Many epidemiologic studies were performed to clarify the protective effect of regular aspirin use on breast cancer risks, but the results remain inconsistent." | 9.05 | Aspirin might reduce the incidence of breast cancer: An updated meta-analysis of 38 observational studies. ( Cao, Y; Tan, A, 2020) |
| "Previous meta-analyses on the relationship between aspirin use and breast cancer risk have drawn inconsistent results." | 8.95 | Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants. ( Lu, L; Shi, L; Wen, Z; Zeng, J, 2017) |
| "Defining novel molecular mechanisms pertinent to aspirin chemoprevention of breast cancer (BC) and to explain controversial epidemiological results in this regard." | 8.93 | Trinucleotide repeat expansions in human breast cancer-susceptibility genes: relevant targets for aspirin chemoprevention? ( Altinoz, MA; Tunalı, NE, 2016) |
| "Previous studies have examined the effect of aspirin intake on the mortality in breast cancer, but the results are inconsistent." | 8.91 | Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies. ( Chen, L; Ma, T; Tang, J; Zhang, X; Zhao, J; Zhong, S, 2015) |
| "NSAIDs and aspirin after but not before diagnosis were associated with improved breast cancer survival, including breast-cancer-specific mortality, all-cause mortality, and relapse/metastasis." | 8.91 | Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. ( Chen, P; Chen, XW; Gao, P; Huang, XZ; Liu, J; Song, YX; Sun, JX; Tsai, CC; Wang, ZN; Xu, HM, 2015) |
| "Previous studies concerning the association between aspirin use and breast cancer risk yielded inconsistent results." | 8.91 | Aspirin use and risk of breast cancer: systematic review and meta-analysis of observational studies. ( Chen, L; Tang, J; Yu, D; Zhang, X; Zhao, J; Zhong, S, 2015) |
| "Animal and in vitro studies suggest that the use of aspirin may be associated with reduced risk for breast cancer, but results from these studies of the association have been inconsistent." | 8.88 | Aspirin use and breast cancer risk: a meta-analysis. ( He, P; Luo, T; Luo, Y; Yan, HM; Yang, YF; Zheng, H, 2012) |
| "To examine the recent epidemiological studies on aspirin use and breast cancer risk published from 2001 to 2005 within a meta-analysis, to investigate reasons for heterogeneity between the individual studies and to analyse a dose-response-relationship considering frequency and duration of use." | 8.84 | Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. ( Blettner, M; Mangiapane, S; Schlattmann, P, 2008) |
| "Overall, the findings show that while aspirin has the potential to inhibit the TNF-α-mediated cell survival pathway, it does not help sensitize breast cancer cells to necroptotic cell death induction." | 8.31 | Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer. ( Bhatia, A; Dahiya, D; Saha, L; Thakur, B, 2023) |
| "Several studies evaluated the association between aspirin use and risk of breast cancer (BC), with inconsistent results." | 8.31 | Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women. ( Botteri, E; Hofvind, S; Løfling, L; Nafisi, S; Støer, NC; Ursin, G, 2023) |
| "Previous studies assessed the prognostic effect of aspirin, statins, and metformin in breast cancer (BC) patients, with inconclusive results." | 8.31 | Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study. ( Andreassen, BK; Botteri, E; Löfling, LL; Støer, NC; Ursin, G, 2023) |
| "Clinical evidence recently suggests that the regular use of aspirin is associated with a lower risk of breast cancer metastasis, but mechanisms remain unclear." | 8.12 | Aspirin suppresses breast cancer metastasis to lung by targeting anoikis resistance. ( Chen, W; Dong, Z; Li, H; Xu, R; Yan, Y; Zhang, H; Zheng, X, 2022) |
| "We investigated the associations of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) with breast cancer risk by the status of COX-2 protein expression." | 8.12 | Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression. ( Colditz, G; Eliassen, AH; Rosner, B; Schedin, P; Tamimi, RM; Wijayabahu, A; Yaghjyan, L, 2022) |
| " This study investigated the effects of anastrozole and antiplatelet therapy (aspirin/clopidogrel cocktail or atopaxar) treatment on the tumour responses of luminal phenotype breast cancer cells and induced hypercoagulation." | 8.02 | Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation. ( Augustine, TN; Xulu, KR, 2021) |
| "Various clinical studies have determined that aspirin shows anticancer effects in many human malignant cancers, including human epidermal growth factor receptor-2 (HER-2)-positive breast cancer." | 7.96 | Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway. ( Guo, L; Hou, N; Li, G; Ling, R; Wang, Z; Wu, Y; Xu, W; Yan, B; Zhang, J, 2020) |
| " Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality." | 7.96 | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. ( Armstrong, K; Bardia, A; Chan, AT; He, W; Iafrate, AJ; Kumar, NP; McCarthy, AM; Moy, B; Regan, S; Welch, M, 2020) |
| "We investigated the associations of aspirin and other non-steroid anti-inflammatory drugs with mammographic breast density (MBD) and their interactions in relation to breast cancer risk." | 7.96 | Associations of aspirin and other anti-inflammatory medications with mammographic breast density and breast cancer risk. ( Colditz, G; Eliassen, AH; Rosner, B; Tamimi, RM; Wijayabahu, A; Yaghjyan, L, 2020) |
| "Microscopic imaging, the formation of 3D multicellular tumour spheroids, immunocytochemistry, flow cytometry, Annexin V Assay, Caspase 3/7 Apoptosis Assay, tube formation assay and analysis, and WST-1 cell viability assay evaluated the formation of MCTS, morphologic changes, cell viability, apoptosis activity and the expression levels of ALDH1A1, CD44 and CD24 on the cell surface, MDA-MB231 triple-negative breast cancer, tamoxifen (Tmx) resistant variant (MDA-MB-231-TmxR)." | 7.96 | A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer. ( Burov, SV; Haq, S; Harless, W; Markvicheva, E; Qorri, B; Sambi, M; Samuel, V; Szewczuk, MR, 2020) |
| "Use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been hypothesized to be associated with reduced risk of breast cancer; however, results of epidemiological studies have been mixed." | 7.96 | Aspirin use and risk of breast cancer in African American women. ( Barber, L; Bertrand, KA; Bethea, TN; Coogan, PF; Gerlovin, H; Palmer, JR; Rosenberg, L, 2020) |
| "The authors hypothesized that epigenetic changes may help to clarify the underlying biologic mechanism linking aspirin use to breast cancer prognosis." | 7.91 | Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study. ( Bradshaw, PT; Chen, J; Cho, YH; Gammon, MD; McCullough, LE; Neugut, AI; Santella, RM; Teitelbaum, SL; Terry, MB; Wang, T; White, AJ; Xu, X, 2019) |
| "To explore the molecular mechanism underlying the inhibitory effects of aspirin against human breast cancer cell proliferation through bioinformatics analysis." | 7.91 | [Bioinformatic analysis of direct protein targets of aspirin against human breast cancer proliferation]. ( Li, X; Qiao, W; Yang, J; Zhang, E; Zhu, X, 2019) |
| "A significant proportion of patients discontinue their aspirin in the time approaching a breast or colorectal cancer-specific death." | 7.91 | End-of-life prescribing of aspirin in patients with breast or colorectal cancer. ( Barron, TI; Bennett, K; Brown, C; Cranfield, F; Murphy, L; Sharp, L; Smith, A; Visvanathan, K, 2019) |
| "The use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced breast cancer risk, but it is not known if this association extends to women at familial or genetic risk." | 7.91 | Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. ( Andrulis, IL; Buys, SS; Chung, WK; Cigler, T; Daly, MB; Dite, GS; Friedlander, ML; Giles, GG; Glendon, G; Hopper, JL; John, EM; Kehm, RD; Knight, JA; Kornhauser, N; Liao, Y; MacInnis, RJ; McLachlan, SA; Milne, RL; Nesci, S; Phillips, KA; Southey, MC; Terry, MB; Vahdat, L; Weideman, PC; Zeinomar, N, 2019) |
| "Studies suggest regular aspirin use decreases breast cancer (BRCA) risk, with high doses exerting an "anti-cancer" effect." | 7.91 | Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis. ( Jordan, CD; Maihle, N; Simmons, J; Sonbol, MB; Tang, SC; Zhou, Y, 2019) |
| "Studies have shown that aspirin and metformin play important roles in chemoprevention and repression of breast cancers, even though the exact mechanism remains unclear." | 7.88 | Aspirin and metformin exhibit antitumor activity in murine breast cancer. ( Du, C; Liu, Y; Luo, F; Wang, Y; Zhang, N; Zhao, M, 2018) |
| "Whether aspirin or other nonsteroidal anti-inflammation drug (NSAID) use is associated with mortality following breast cancer remains unclear." | 7.88 | Pre-diagnostic aspirin use and mortality after breast cancer. ( Bradshaw, PT; Gammon, MD; McClain, KM; Neugut, AI; Parada, H; Teitelbaum, SL; Terry, MB; Wang, T, 2018) |
| "The use of aspirin has been associated with improved survival in patients with breast cancer, but the results have been mixed." | 7.88 | The impact of aspirin use on breast cancer subtype and clinical course. ( Carrigan, E; Li, YR; Nguyen, J; Ro, V; So, A; Steel, L; Tchou, J; Williams, AD, 2018) |
| "Observational studies of aspirin use and breast cancer risk have provided inconsistent results." | 7.88 | Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study. ( Bens, A; Cronin-Fenton, D; Dehlendorff, C; Ejlertsen, B; Friis, S; Jensen, MB; Kroman, N; Mellemkjær, L, 2018) |
| "Results from previous studies indicate that use of low-dose aspirin may improve breast cancer prognosis." | 7.88 | No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study. ( Ekberg, S; Eloranta, S; Fredriksson, I; Frisk, G; Lambe, M; Lidbrink, E; Smedby, KE; Sund, M, 2018) |
| "Tamoxifen is still the most commonly used endocrine therapy drug for estrogen receptor (ER)-positive breast cancer patients and has an excellent outcome, but tamoxifen resistance remains a great impediment to successful treatment." | 7.85 | Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. ( Cheng, R; Cui, JW; Fang, ZY; Li, P; Li, YX; Liu, XL; Liu, YJ; Lu, SY; Wang, Z; Wei, W; Wu, XQ; Yang, M; Zhou, Y; Zhu, LZ; Zou, L, 2017) |
| "Regular users of aspirin may have reduced risk of breast cancer." | 7.85 | Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study. ( Bernstein, L; Canchola, AJ; Chung, NT; Clarke, CA; Lacey, JV; Moy, LM; Neuhausen, SL, 2017) |
| "Our findings suggest that a cumulative aspirin dosage of more than 88,900 mg daily was associated with a reduced risk of breast cancer in women with diabetes." | 7.85 | Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan. ( Chiou, JY; Huang, CN; Kornelius, E; Lai, YR; Lo, SC; Peng, CH; Yang, YS, 2017) |
| "Objective To explore the effect of aspirin on the apoptosis and autophagy of human epidermal growth factor receptor 2 (HER2)-positive AU-565 breast cancer cells and triple negative MDA-MB-231 breast cancer cells." | 7.85 | [Aspirin inhibits the proliferation of breast cancer cells via inducing apoptosis and autophagy]. ( Kong, J; Ling, R; Wang, Z; Wu, Y; Zhang, J, 2017) |
| "Preclinical evidence from breast cancer cell lines and animal models suggest that aspirin could have anti-cancer properties." | 7.85 | Low-dose aspirin use and survival in breast cancer patients: A nationwide cohort study. ( Cardwell, CR; Hughes, CM; Mc Menamin, ÚC; Murray, LJ, 2017) |
| "To evaluate the association of aspirin and other nonsteroidal anti-inflammatory drugs with the incidence of postmenopausal breast cancer for risk subgroups defined by selected nonmodifiable or difficult to modify breast cancer risk factors in order to better understand the potential risk-benefit ratio for targeted chemoprevention." | 7.83 | Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. ( Anderson, KE; Bardia, A; Cerhan, JR; Ebbert, JO; Keenan, TE; Lazovich, D; Limburg, PJ; Olson, JE; Vachon, CM; Vierkant, RA; Wang, AH, 2016) |
| "Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models." | 7.83 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016) |
| "A review of the literature finds that women diagnosed with breast cancer, who were on an aspirin regimen, experienced a decreased risk of distant metastases and death." | 7.83 | Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. ( Abukhdeir, AM; Cobleigh, MA; Najor, MS; Ruby, CE; Turturro, SB, 2016) |
| "Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and selective COX-2 inhibitors may improve outcomes in breast cancer patients." | 7.83 | Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence. ( Ahern, TP; Christiansen, P; Cronin-Fenton, DP; Ejlertsen, B; Heide-Jørgensen, U; Lash, TL; Sørensen, HT, 2016) |
| "Aspirin use has been associated with significant reductions in breast cancer-related mortality in some observational studies." | 7.81 | De Novo Post-Diagnosis Aspirin Use and Mortality in Women with Stage I-III Breast Cancer. ( Barron, TI; Bennett, K; Brown, C; Murphy, LM; Sharp, L; Visvanathan, K, 2015) |
| " Aspirin (ASA), in particular, is associated with reduced breast cancer incidence but gastrointestinal toxicity has limited its usefulness." | 7.81 | A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties. ( Alvarez, M; Frasor, J; Kastrati, I; Litosh, VA; Thatcher, GR; Zhao, S, 2015) |
| "Recent observational studies indicate that post-diagnostic use of aspirin in breast cancer patients may protect against cancer progression perhaps by inhibiting cyclooxygenase-2 dependent mechanisms." | 7.80 | Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. ( Cardwell, CR; Cooper, JA; Hughes, CM; Murray, LJ; Powe, DG, 2014) |
| " All community prescriptions for aspirin in women with breast cancer were extracted and use postdiagnosis for each individual examined using Cox's proportional hazard models." | 7.80 | Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. ( Fraser, DM; McCowan, C; Sullivan, FM; Thompson, AM, 2014) |
| " Therefore, we examined the association between recent (1 year) prediagnostic use of aspirin (COX1/COX2 inhibitor), lymph node involvement at breast cancer diagnosis, and breast cancer-specific mortality." | 7.80 | Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study. ( Barron, TI; Bennett, K; Flahavan, EM; Sharp, L; Visvanathan, K, 2014) |
| "The associations between use of aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen and breast cancer incidence in postmenopausal women are uncertain." | 7.78 | Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. ( Collins, LC; Hankinson, SE; Rosner, B; Smith-Warner, SA; Willett, WC; Zhang, X, 2012) |
| "The purpose of this study is to investigate the combined effects of exemestane and aspirin on MCF-7 human breast cancer cells." | 7.78 | Synergistic effects of exemestane and aspirin on MCF-7 human breast cancer cells. ( Du, YY; Hu, LX; Pan, YY; Zhang, Y, 2012) |
| "We evaluated the relations of current use of aspirin, non-aspirin NSAIDs, and acetaminophen with breast cancer incidence in the Black Women's Health Study." | 7.77 | Regular aspirin use and breast cancer risk in US Black women. ( Boggs, DA; Bosco, JL; Hatch, EE; Palmer, JR; Rosenberg, L, 2011) |
| "Animal and in vitro studies suggest that aspirin may inhibit breast cancer metastasis." | 7.76 | Aspirin intake and survival after breast cancer. ( Chen, WY; Hankinson, SE; Hertzmark, E; Holmes, MD; Li, L; Spiegelman, D, 2010) |
| "We assessed the associations for use of aspirin, other NSAIDs, and acetaminophen with breast cancer risk among premenopausal women in the prospective Nurses' Health Study II." | 7.75 | Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. ( Chen, WY; Eliassen, AH; Hankinson, SE; Hunter, DJ; Spiegelman, D; Willett, WC, 2009) |
| "The ability of aspirin to trigger apoptosis in cancer cells is well known and is consistent with the clinical and epidemiological evidence on its chemopreventive effects in curtailing epithelial cancers, including breast cancer." | 7.75 | Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. ( Abbruscato, TJ; Alfonso, LF; Arumugam, TV; Bhat, GJ; Srivenugopal, KS; Weidanz, JA, 2009) |
| "In a monocentric prospective study, patients with stage II-IV breast cancer, who underwent CVC insertion for continuous infusional chemotherapy, were assigned to receive low-dose aspirin (100 mg daily)." | 7.74 | Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. ( Balduzzi, A; Cardillo, A; Colleoni, M; Curigliano, G; Dellapasqua, S; Ghisini, R; Goldhirsch, A; Lunghi, L; Orlando, L; Peruzzotti, G; Torrisi, R, 2007) |
| "Use of nonsteroidal anti-inflammatory drugs (NSAIDs), particularly aspirin, has consistently been associated with reduced risk of breast cancer in case-control studies." | 7.73 | Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. ( Calle, EE; Connell, CJ; Feigelson, HS; Flanders, WD; Henley, SJ; Jacobs, EJ; Patel, AV; Rodriguez, C; Thun, MJ, 2005) |
| "Of the limited number of epidemiological investigations on aspirin (and other nonsteroidal anti-inflammatory drugs) and breast cancer, the majority observe a protective role, yet only a few report dose-response effects for frequency or duration of use." | 7.73 | Association of regular aspirin use and breast cancer risk. ( Menezes, RJ; Mirand, AL; Moysich, KB; Swede, H, 2005) |
| "Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with a decrease in the risk of several cancers, including breast cancer." | 7.72 | Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. ( Britton, JA; Dannenberg, AJ; Gammon, MD; Neugut, AI; Subbaramaiah, K; Tawfik, H; Teitelbaum, SL; Terry, MB; Zhang, FF, 2004) |
| "Previous epidemiological studies have suggested that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with reduced risk of breast cancer, but some studies have been limited in their ability to separate the effects of aspirin from other NSAIDs or to account for breast cancer risk factors." | 7.71 | Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. ( Anderson, KE; Folsom, AR; Johnson, TW; Lazovich, D, 2002) |
| "We analyzed data from the prospective Nurses' Health Study to evaluate the influence of aspirin use on breast cancer risk." | 7.69 | Prospective study of regular aspirin use and the risk of breast cancer. ( Colditz, GA; Egan, KM; Giovannucci, E; Rosner, BA; Stampfer, MJ, 1996) |
| " We therefore assessed the effect of Indomethacin and aspirin on some parameters of calcium metabolism in patients with breast cancer." | 7.65 | Failure of indomethacin to reduce hypercalcemia in patients with breast cancer. ( Bondy, PK; Coombes, RC; Neville, AM; Powles, TJ, 1976) |
| " This study aimed to assess the relationship between aspirin use and BC risk, and to determine if there is a dose-response relationship between aspirin and BC risk." | 7.01 | Prophylactic aspirin intake and breast cancer risk; A systematic review and meta-analysis of observational cohort studies. ( Bakierzynska, M; Corrigan, M; Cullinane, MC; Redmond, HP, 2023) |
| "Aspirin could reduce the risk of cancer metastasis." | 6.87 | The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. ( Chen, Y; Hu, X; Lv, Y; Lv, Z; Ni, C; Weng, X; Xia, W; Xin, Y; Xu, Q; Yang, L; Yuan, H; Zhang, W, 2018) |
| "Despite advances in breast cancer treatment, mortality from breast cancer is still high." | 6.52 | Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review. ( Ch Yiannakopoulou, E, 2015) |
| "Breast cancer is a neoplasm with the highest incidence and mortality rate among young women worldwide." | 6.50 | Clinical evidence of the relationship between aspirin and breast cancer risk (review). ( Camacho-Zavala, E; García-Castillo, V; González, GF; Jacobo-Herrera, NJ; Pérez-Plasencia, C; Urrutia, EL; Zentella-Dehesa, A, 2014) |
| "Aspirin treatment modified metabolites involved in suppressing lipogenesis, oxidative stress, and neoplastic formation." | 5.56 | Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth. ( Chiu, HH; Hsieh, CC; Kuo, CH; Wang, CH, 2020) |
| "Background Breast cancer is highly prevalent among women worldwide." | 5.48 | Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. ( Amaral, MEA; Campos, MM; de Azevedo Junior, WF; Leite, CE; Nery, LR, 2018) |
| "Ibuprofen was not effective in the comet assay but showed a significant reduction in MN frequency, with the nano formulation being more effective." | 5.48 | Aspirin and ibuprofen, in bulk and nanoforms: Effects on DNA damage in peripheral lymphocytes from breast cancer patients and healthy individuals. ( Anderson, D; Baumgartner, A; Dandah, O; Isreb, M; Linforth, R; Najafzadeh, M; Tait, C, 2018) |
| "Aspirin treatment significantly inhibited the proliferation of 4T1 cells, and decreased the production of MCP-1 and PAI-1 in both the Ad-CM model and co-culture system." | 5.43 | Aspirin Breaks the Crosstalk between 3T3-L1 Adipocytes and 4T1 Breast Cancer Cells by Regulating Cytokine Production. ( Hsieh, CC; Huang, YS, 2016) |
| "Treatment with aspirin prior to chemotherapy suppressed the acquisition of chemoresistance by perturbing the nuclear translocation of NFκB in preexisting CSCs." | 5.43 | Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFκB-IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells. ( Das, T; De, S; Jana, D; Kajal, K; Khan, P; Manna, A; Mazumdar, M; Mukherjee, S; Saha, S; Sarkar, DK, 2016) |
| "Estrogen receptor negative (ER(-)) breast cancer is aggressive, responds poorly to current treatments and has a poor prognosis." | 5.42 | Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. ( Chattopadhyay, M; Kashfi, K; Kodela, R; Nath, N; Nazarenko, A; Rodes, DB, 2015) |
| "Efficacy of PA-2 was evaluated in human breast cancer cells in vitro, and in orthotopic and subcutaneous TNBC xenografts in nude mice." | 5.40 | Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. ( Alston, N; Cheng, KW; Huang, L; Mackenzie, GG; Ouyang, N; Rigas, B; Sun, Y; Vrankova, K; Wong, CC, 2014) |
| "Associations with breast cancer-specific mortality differed by IA ancestry; SOCS1 rs193779, STAT3 rs1026916, and STAT4 rs11685878 associations were limited to women with low IA ancestry, and associations with JAK1 rs2780890, rs2254002, and rs310245 and STAT1 rs11887698 were observed among women with high IA ancestry." | 5.40 | Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study. ( Hines, LM; John, EM; Lundgreen, A; Slattery, ML; Stern, MC; Torres-Mejia, G; Wolff, RK, 2014) |
| "Aspirin has been reported to trigger apoptosis in various cancer cell lines." | 5.39 | Direct regulation of caspase‑3 by the transcription factor AP‑2α is involved in aspirin‑induced apoptosis in MDA‑MB‑453 breast cancer cells. ( Ding, X; He, Q; Hu, X; Li, L; Li, W; Wei, K; Xiang, S; Yan, F; Zhang, J; Zhong, Y, 2013) |
| "Through 2005, 1,581 incident breast cancer cases were observed." | 5.37 | Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. ( Anderson, KE; Bardia, A; Cerhan, JR; Lazovich, D; Limburg, PJ; Olson, JE; Vachon, CM; Vierkant, RA; Wang, AH, 2011) |
| "Aspirin and NSAIDs inhibit COX-2." | 5.37 | COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. ( Chen, WY; Colditz, GA; Collins, L; Hankinson, SE; Holmes, MD; Schnitt, SJ; Tamimi, RM, 2011) |
| "Breast cancer is one of the most common tumors in women of Western countries." | 5.36 | Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. ( de Lumen, BO; Hernández-Ledesma, B; Hsieh, CC, 2010) |
| "The occurrence of metastasis was ascertained monthly by a qualified oncologist, and confirmed, if necessary, by biopsy." | 5.36 | Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected]. ( Bhattacharyya, M; Chakraborty, S; Ghosh, R; Girish, GV; Sinha, AK, 2010) |
| "We also evaluate breast cancer associations with aspirin and nonsteroidal anti-inflammatory drugs." | 5.34 | IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. ( Baumgartner, KB; Baumgartner, R; Byers, T; Curtin, K; Giuliano, AR; Slattery, ML; Sweeney, C; Wolff, RR, 2007) |
| "Maspin, an anti breast cancer protein, is produced in the normal mammary cells but not in malignant cells in breast cancer." | 5.33 | Restoration by aspirin of impaired plasma maspin level in human breast cancer. ( Bhattacharya, G; Chakraborty, K; Girish, GV; Kahn, NN; Sinha, AK; Sinha, N, 2006) |
| "Among these breast cancers those that are estrogen-responsive respond well to existing therapeutic regimens while estrogen non-responsive cancers metastasize widely, demonstrate a high relapse rate, and respond poorly to therapy." | 5.31 | Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. ( Cakir, Y; Plummer, HK; Schuller, HM; Tithof, PK, 2002) |
| "Preclinical, epidemiological, and randomised data indicate that aspirin might prevent tumour development and metastasis, leading to reduced cancer mortality, particularly for gastro-oesophageal and colorectal cancer." | 5.30 | Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. ( Adams, R; Berkman, L; Bridgewater, J; Cafferty, F; Cameron, D; Crossley, A; Din, F; Falk, S; Gilbert, D; Graham, J; Gupta, K; Henson, V; Hubner, R; Iveson, T; Jankowski, J; Joharatnam-Hogan, N; Khabra, K; Kunene, V; Kynaston, H; Langley, R; Patel, K; Pramesh, CS; Ring, A; Rowley, S; Sothi, S; Swinson, D; Thomas, A; Underwood, T; Warner, N; Wilson, R, 2019) |
| "23 (60%) of 38 human breast carcinomas had significant in-vitro osteolytic activity." | 5.26 | Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. ( Dowsett, M; Easty, DM; Easty, GC; Neville, AM; Powles, TJ, 1976) |
| "Prediagnostic aspirin use was not found to be associated with lower breast cancer-specific mortality (HR, 0." | 5.22 | Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Barron, TI; Black, A; Bradley, MC; Freedman, AN, 2016) |
| "Aspirin (ASA) use has been associated with improved breast cancer survival in several prospective studies." | 5.19 | Aspirin intake and breast cancer survival - a nation-wide study using prospectively recorded data in Sweden. ( Adami, HO; Andersson, TM; Askling, J; Holm, J; Holmes, MD; Lundholm, C; Olsson, H; Pawitan, Y; Smedby, KE, 2014) |
| "Epidemiologic studies suggest a reduced risk of breast cancer among women who use aspirin." | 5.19 | Aspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial. ( Duggan, C; McTiernan, A; Wang, CY; Xiao, L, 2014) |
| " We undertook a prospective study to determine the influence of a 45-day course of aspirin therapy on circulating and intraplatelet levels of selected proangiogenic (vascular endothelial growth factor [VEGF]) and antiangiogenic (thrombospondin-1 [TSP-1]) proteins, and platelet protein release in women diagnosed with breast cancer who were receiving tamoxifen therapy." | 5.17 | Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. ( Holmes, CE; Jasielec, J; Levis, JE; Muss, HB; Skelly, J, 2013) |
| " To test whether disruption of platelet function with clopidogrel and aspirin would decrease the number of circulating tumor cells (CTCs) in patients with metastatic breast cancer, a randomized phase II study was performed." | 5.17 | A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. ( Eby, CS; Johnson, F; Lammers, PE; Naughton, MJ; Pluard, TJ; Roop, RP; Schneider, JG; Van Poznak, C; Weilbaecher, KN, 2013) |
| "Epidemiologic studies suggest a reduced risk of breast cancer among women who regularly use aspirin; a plausible mechanism is through aspirin effect on mammographic breast density, a breast cancer risk factor, possibly mediated through aspirin interference with estrogen synthesis." | 5.14 | No effect of aspirin on mammographic density in a randomized controlled clinical trial. ( Aiello Bowles, EJ; Buist, DS; McTiernan, A; Potter, J; Rossing, MA; Sorensen, B; Urban, N; Wang, CY; White, E; Xiao, L, 2009) |
| "The Women's Health Study trial previously reported no overall effect of low-dose aspirin (100 mg every other day) on invasive breast cancer over an average of 10 years of treatment." | 5.13 | Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. ( Buring, JE; Cook, NR; Lee, IM; Manson, JE; Zhang, SM, 2008) |
| "VEGF and endostatin concentrations were measured with a quantitative immunoassay before and after 1 to 5 weeks of treatment in 30 women with breast cancer treated with either tamoxifen (n = 14) or aromatase inhibitors (n = 16)." | 5.13 | Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. ( Holmes, CE; Howard, AB; Huang, JC; Muss, HB; Pace, TR, 2008) |
| "Some evidence shows that aspirin can reduce the morbidity and mortality of different cancers, including breast cancer." | 5.12 | Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019. ( Guo, C; Han, T; Jiang, Y; Ma, S; Qu, G; Sun, C; Sun, Y; Zhang, H; Zhou, Q, 2021) |
| "The purpose of this study is to investigate whether aspirin improves the prognosis of breast cancer patients by meta analysis." | 5.12 | Effect of aspirin use on survival benefits of breast cancer patients: A meta-analysis. ( Liu, A; Liu, J; Wu, X; Yang, M; Zheng, F, 2021) |
| "Many epidemiologic studies were performed to clarify the protective effect of regular aspirin use on breast cancer risks, but the results remain inconsistent." | 5.05 | Aspirin might reduce the incidence of breast cancer: An updated meta-analysis of 38 observational studies. ( Cao, Y; Tan, A, 2020) |
| "Previous meta-analyses on the relationship between aspirin use and breast cancer risk have drawn inconsistent results." | 4.95 | Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants. ( Lu, L; Shi, L; Wen, Z; Zeng, J, 2017) |
| "Defining novel molecular mechanisms pertinent to aspirin chemoprevention of breast cancer (BC) and to explain controversial epidemiological results in this regard." | 4.93 | Trinucleotide repeat expansions in human breast cancer-susceptibility genes: relevant targets for aspirin chemoprevention? ( Altinoz, MA; Tunalı, NE, 2016) |
| "Previous studies have examined the effect of aspirin intake on the mortality in breast cancer, but the results are inconsistent." | 4.91 | Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies. ( Chen, L; Ma, T; Tang, J; Zhang, X; Zhao, J; Zhong, S, 2015) |
| "NSAIDs and aspirin after but not before diagnosis were associated with improved breast cancer survival, including breast-cancer-specific mortality, all-cause mortality, and relapse/metastasis." | 4.91 | Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. ( Chen, P; Chen, XW; Gao, P; Huang, XZ; Liu, J; Song, YX; Sun, JX; Tsai, CC; Wang, ZN; Xu, HM, 2015) |
| "Previous studies concerning the association between aspirin use and breast cancer risk yielded inconsistent results." | 4.91 | Aspirin use and risk of breast cancer: systematic review and meta-analysis of observational studies. ( Chen, L; Tang, J; Yu, D; Zhang, X; Zhao, J; Zhong, S, 2015) |
| "Animal and in vitro studies suggest that the use of aspirin may be associated with reduced risk for breast cancer, but results from these studies of the association have been inconsistent." | 4.88 | Aspirin use and breast cancer risk: a meta-analysis. ( He, P; Luo, T; Luo, Y; Yan, HM; Yang, YF; Zheng, H, 2012) |
| "Evidence clearly shows a chemopreventive effect for aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer and probably other cancer types; however, data on the risk-benefit profile for cancer prevention are insufficient and no definitive recommendations can be made." | 4.85 | Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. ( Baron, JA; Brown, PH; Burn, J; Cuzick, J; Greenwald, P; Jankowski, J; La Vecchia, C; Meyskens, F; Otto, F; Senn, HJ; Thun, M, 2009) |
| "Studies that examined the association between risk of breast cancer and use of NSAIDs, including aspirin and ibuprofen, that were published between January 1, 1966, and July 1, 2008, were identified using Medline, EMBASE, and other databases." | 4.84 | Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. ( Etminan, M; Regueira-Méndez, C; Takkouche, B, 2008) |
| "To examine the recent epidemiological studies on aspirin use and breast cancer risk published from 2001 to 2005 within a meta-analysis, to investigate reasons for heterogeneity between the individual studies and to analyse a dose-response-relationship considering frequency and duration of use." | 4.84 | Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. ( Blettner, M; Mangiapane, S; Schlattmann, P, 2008) |
| " Randomized trials have found that in specific patient subgroups, tamoxifen and raloxifene decreased the occurrence of breast cancer, and lovastatin and aspirin decreased the frequency of CAD events." | 4.80 | Preventing heart disease and cancer. What randomized, primary-prevention studies show. ( Lush, DT, 1999) |
| "Only case-control studies and most of the prospective cohort studies showed a reduction of colorectal cancer incidence in regular aspirin users." | 4.80 | [Aspirin against cancer]. ( de Gramont, A; Mabro, M, 2000) |
| "Overall, the findings show that while aspirin has the potential to inhibit the TNF-α-mediated cell survival pathway, it does not help sensitize breast cancer cells to necroptotic cell death induction." | 4.31 | Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer. ( Bhatia, A; Dahiya, D; Saha, L; Thakur, B, 2023) |
| "Several studies evaluated the association between aspirin use and risk of breast cancer (BC), with inconsistent results." | 4.31 | Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women. ( Botteri, E; Hofvind, S; Løfling, L; Nafisi, S; Støer, NC; Ursin, G, 2023) |
| "Previous studies assessed the prognostic effect of aspirin, statins, and metformin in breast cancer (BC) patients, with inconclusive results." | 4.31 | Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study. ( Andreassen, BK; Botteri, E; Löfling, LL; Støer, NC; Ursin, G, 2023) |
| "Clinical evidence recently suggests that the regular use of aspirin is associated with a lower risk of breast cancer metastasis, but mechanisms remain unclear." | 4.12 | Aspirin suppresses breast cancer metastasis to lung by targeting anoikis resistance. ( Chen, W; Dong, Z; Li, H; Xu, R; Yan, Y; Zhang, H; Zheng, X, 2022) |
| "Cell strength appears to have increased due to aspirin's intervention on actin filaments and cytoskeletons, and the mechanical properties of breast cancer cells have become more similar to those of normal cells." | 4.12 | The Effect of Acetylsalicylic Acid (Asa) on the Mechanical Properties of Breast Cancer Epithelial Cells. ( Khorramymehr, S; Milani, D; Vasaghi-Gharamaleki, B, 2022) |
| "The nonsteroidal anti-inflammatory drug aspirin is an agent of interest for breast cancer prevention." | 4.12 | Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use. ( Acheampong, T; Agovino, M; Athilat, S; Lee Argov, EJ; Rodriguez, CB; Tehranifar, P; Terry, MB; Wei, Y, 2022) |
| " Aspirin has been found to induce reprogramming factors of mesenchymal-to-epithelial transition in breast cancer cells." | 4.12 | A novel role for aspirin in enhancing the reprogramming function of miR-302/367 cluster and breast tumor suppression. ( Ardekani, AM; Eghtedari, A; Javeri, A; Rezania, MA; Taha, MF, 2022) |
| "We investigated the associations of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) with breast cancer risk by the status of COX-2 protein expression." | 4.12 | Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression. ( Colditz, G; Eliassen, AH; Rosner, B; Schedin, P; Tamimi, RM; Wijayabahu, A; Yaghjyan, L, 2022) |
| "Epidemiologic evidence is insufficient to draw conclusions on the impact of low-dose aspirin use on breast cancer risk, and the potential impact of other antiplatelet drugs such as clopidogrel needs to be explored." | 4.02 | Antiplatelet Drug Use and Breast Cancer Risk in a Prospective Cohort of Postmenopausal Women. ( Al Rahmoun, M; Cairat, M; Dossus, L; Fournier, A; Gunter, MJ; Severi, G, 2021) |
| " This study investigated the effects of anastrozole and antiplatelet therapy (aspirin/clopidogrel cocktail or atopaxar) treatment on the tumour responses of luminal phenotype breast cancer cells and induced hypercoagulation." | 4.02 | Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation. ( Augustine, TN; Xulu, KR, 2021) |
| "Various clinical studies have determined that aspirin shows anticancer effects in many human malignant cancers, including human epidermal growth factor receptor-2 (HER-2)-positive breast cancer." | 3.96 | Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway. ( Guo, L; Hou, N; Li, G; Ling, R; Wang, Z; Wu, Y; Xu, W; Yan, B; Zhang, J, 2020) |
| " Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality." | 3.96 | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. ( Armstrong, K; Bardia, A; Chan, AT; He, W; Iafrate, AJ; Kumar, NP; McCarthy, AM; Moy, B; Regan, S; Welch, M, 2020) |
| "We investigated the associations of aspirin and other non-steroid anti-inflammatory drugs with mammographic breast density (MBD) and their interactions in relation to breast cancer risk." | 3.96 | Associations of aspirin and other anti-inflammatory medications with mammographic breast density and breast cancer risk. ( Colditz, G; Eliassen, AH; Rosner, B; Tamimi, RM; Wijayabahu, A; Yaghjyan, L, 2020) |
| "Microscopic imaging, the formation of 3D multicellular tumour spheroids, immunocytochemistry, flow cytometry, Annexin V Assay, Caspase 3/7 Apoptosis Assay, tube formation assay and analysis, and WST-1 cell viability assay evaluated the formation of MCTS, morphologic changes, cell viability, apoptosis activity and the expression levels of ALDH1A1, CD44 and CD24 on the cell surface, MDA-MB231 triple-negative breast cancer, tamoxifen (Tmx) resistant variant (MDA-MB-231-TmxR)." | 3.96 | A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer. ( Burov, SV; Haq, S; Harless, W; Markvicheva, E; Qorri, B; Sambi, M; Samuel, V; Szewczuk, MR, 2020) |
| "Use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been hypothesized to be associated with reduced risk of breast cancer; however, results of epidemiological studies have been mixed." | 3.96 | Aspirin use and risk of breast cancer in African American women. ( Barber, L; Bertrand, KA; Bethea, TN; Coogan, PF; Gerlovin, H; Palmer, JR; Rosenberg, L, 2020) |
| "The authors hypothesized that epigenetic changes may help to clarify the underlying biologic mechanism linking aspirin use to breast cancer prognosis." | 3.91 | Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study. ( Bradshaw, PT; Chen, J; Cho, YH; Gammon, MD; McCullough, LE; Neugut, AI; Santella, RM; Teitelbaum, SL; Terry, MB; Wang, T; White, AJ; Xu, X, 2019) |
| "To explore the molecular mechanism underlying the inhibitory effects of aspirin against human breast cancer cell proliferation through bioinformatics analysis." | 3.91 | [Bioinformatic analysis of direct protein targets of aspirin against human breast cancer proliferation]. ( Li, X; Qiao, W; Yang, J; Zhang, E; Zhu, X, 2019) |
| "A significant proportion of patients discontinue their aspirin in the time approaching a breast or colorectal cancer-specific death." | 3.91 | End-of-life prescribing of aspirin in patients with breast or colorectal cancer. ( Barron, TI; Bennett, K; Brown, C; Cranfield, F; Murphy, L; Sharp, L; Smith, A; Visvanathan, K, 2019) |
| "The use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced breast cancer risk, but it is not known if this association extends to women at familial or genetic risk." | 3.91 | Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. ( Andrulis, IL; Buys, SS; Chung, WK; Cigler, T; Daly, MB; Dite, GS; Friedlander, ML; Giles, GG; Glendon, G; Hopper, JL; John, EM; Kehm, RD; Knight, JA; Kornhauser, N; Liao, Y; MacInnis, RJ; McLachlan, SA; Milne, RL; Nesci, S; Phillips, KA; Southey, MC; Terry, MB; Vahdat, L; Weideman, PC; Zeinomar, N, 2019) |
| "Studies suggest regular aspirin use decreases breast cancer (BRCA) risk, with high doses exerting an "anti-cancer" effect." | 3.91 | Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis. ( Jordan, CD; Maihle, N; Simmons, J; Sonbol, MB; Tang, SC; Zhou, Y, 2019) |
| "Our findings suggest that concurrent use of glucocorticoids, ACE inhibitors, aspirin, NSAIDs, selective COX-2 inhibitors, digoxin, and opioids has little impact on breast cancer recurrence." | 3.88 | Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database. ( Ahern, TP; Christiansen, P; Cronin-Fenton, D; Damkier, P; Ejlertsen, B; Lash, TL; Sørensen, HT, 2018) |
| "Studies have shown that aspirin and metformin play important roles in chemoprevention and repression of breast cancers, even though the exact mechanism remains unclear." | 3.88 | Aspirin and metformin exhibit antitumor activity in murine breast cancer. ( Du, C; Liu, Y; Luo, F; Wang, Y; Zhang, N; Zhao, M, 2018) |
| "Whether aspirin or other nonsteroidal anti-inflammation drug (NSAID) use is associated with mortality following breast cancer remains unclear." | 3.88 | Pre-diagnostic aspirin use and mortality after breast cancer. ( Bradshaw, PT; Gammon, MD; McClain, KM; Neugut, AI; Parada, H; Teitelbaum, SL; Terry, MB; Wang, T, 2018) |
| "The use of aspirin has been associated with improved survival in patients with breast cancer, but the results have been mixed." | 3.88 | The impact of aspirin use on breast cancer subtype and clinical course. ( Carrigan, E; Li, YR; Nguyen, J; Ro, V; So, A; Steel, L; Tchou, J; Williams, AD, 2018) |
| "Observational studies of aspirin use and breast cancer risk have provided inconsistent results." | 3.88 | Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study. ( Bens, A; Cronin-Fenton, D; Dehlendorff, C; Ejlertsen, B; Friis, S; Jensen, MB; Kroman, N; Mellemkjær, L, 2018) |
| "Results from previous studies indicate that use of low-dose aspirin may improve breast cancer prognosis." | 3.88 | No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study. ( Ekberg, S; Eloranta, S; Fredriksson, I; Frisk, G; Lambe, M; Lidbrink, E; Smedby, KE; Sund, M, 2018) |
| "Tamoxifen is still the most commonly used endocrine therapy drug for estrogen receptor (ER)-positive breast cancer patients and has an excellent outcome, but tamoxifen resistance remains a great impediment to successful treatment." | 3.85 | Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. ( Cheng, R; Cui, JW; Fang, ZY; Li, P; Li, YX; Liu, XL; Liu, YJ; Lu, SY; Wang, Z; Wei, W; Wu, XQ; Yang, M; Zhou, Y; Zhu, LZ; Zou, L, 2017) |
| "Regular users of aspirin may have reduced risk of breast cancer." | 3.85 | Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study. ( Bernstein, L; Canchola, AJ; Chung, NT; Clarke, CA; Lacey, JV; Moy, LM; Neuhausen, SL, 2017) |
| "Our findings suggest that a cumulative aspirin dosage of more than 88,900 mg daily was associated with a reduced risk of breast cancer in women with diabetes." | 3.85 | Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan. ( Chiou, JY; Huang, CN; Kornelius, E; Lai, YR; Lo, SC; Peng, CH; Yang, YS, 2017) |
| "Objective To explore the effect of aspirin on the apoptosis and autophagy of human epidermal growth factor receptor 2 (HER2)-positive AU-565 breast cancer cells and triple negative MDA-MB-231 breast cancer cells." | 3.85 | [Aspirin inhibits the proliferation of breast cancer cells via inducing apoptosis and autophagy]. ( Kong, J; Ling, R; Wang, Z; Wu, Y; Zhang, J, 2017) |
| " We investigated use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitors (SSRIs), and statins and risk of postoperative red blood cell transfusion in breast cancer patients." | 3.85 | Use of prescription drugs and risk of postoperative red blood cell transfusion in breast cancer patients: a Danish population-based cohort study. ( Christiansen, PM; Cronin-Fenton, D; Erikstrup, C; Kristensen, NR; Møller, BK; Nørgaard, M; Pedersen, AB; Thomsen, AML, 2017) |
| "Preclinical evidence from breast cancer cell lines and animal models suggest that aspirin could have anti-cancer properties." | 3.85 | Low-dose aspirin use and survival in breast cancer patients: A nationwide cohort study. ( Cardwell, CR; Hughes, CM; Mc Menamin, ÚC; Murray, LJ, 2017) |
| "Observational and biologic studies suggest that aspirin is a promising prevention therapy for breast cancer." | 3.85 | Aspirin use is associated with lower mammographic density in a large screening cohort. ( Conant, EF; Cuke, M; Kontos, D; Oustimov, A; Sprague, BL; Synnstvedt, MB; Wood, ME, 2017) |
| "To evaluate the association of aspirin and other nonsteroidal anti-inflammatory drugs with the incidence of postmenopausal breast cancer for risk subgroups defined by selected nonmodifiable or difficult to modify breast cancer risk factors in order to better understand the potential risk-benefit ratio for targeted chemoprevention." | 3.83 | Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. ( Anderson, KE; Bardia, A; Cerhan, JR; Ebbert, JO; Keenan, TE; Lazovich, D; Limburg, PJ; Olson, JE; Vachon, CM; Vierkant, RA; Wang, AH, 2016) |
| "Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models." | 3.83 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016) |
| "A review of the literature finds that women diagnosed with breast cancer, who were on an aspirin regimen, experienced a decreased risk of distant metastases and death." | 3.83 | Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. ( Abukhdeir, AM; Cobleigh, MA; Najor, MS; Ruby, CE; Turturro, SB, 2016) |
| "Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and selective COX-2 inhibitors may improve outcomes in breast cancer patients." | 3.83 | Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence. ( Ahern, TP; Christiansen, P; Cronin-Fenton, DP; Ejlertsen, B; Heide-Jørgensen, U; Lash, TL; Sørensen, HT, 2016) |
| "Aspirin use has been associated with significant reductions in breast cancer-related mortality in some observational studies." | 3.81 | De Novo Post-Diagnosis Aspirin Use and Mortality in Women with Stage I-III Breast Cancer. ( Barron, TI; Bennett, K; Brown, C; Murphy, LM; Sharp, L; Visvanathan, K, 2015) |
| " Aspirin (ASA), in particular, is associated with reduced breast cancer incidence but gastrointestinal toxicity has limited its usefulness." | 3.81 | A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties. ( Alvarez, M; Frasor, J; Kastrati, I; Litosh, VA; Thatcher, GR; Zhao, S, 2015) |
| "Recent observational studies indicate that post-diagnostic use of aspirin in breast cancer patients may protect against cancer progression perhaps by inhibiting cyclooxygenase-2 dependent mechanisms." | 3.80 | Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. ( Cardwell, CR; Cooper, JA; Hughes, CM; Murray, LJ; Powe, DG, 2014) |
| "Overall, this study suggested that both celecoxib and aspirin could prevent breast cancer growth by regulating proteins in the cell cycle and apoptosis without blocking estrogen synthesis." | 3.80 | Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice. ( Chan, FL; Chen, S; Leung, LK; Li, F; Lin, SM; Wong, TY, 2014) |
| " All community prescriptions for aspirin in women with breast cancer were extracted and use postdiagnosis for each individual examined using Cox's proportional hazard models." | 3.80 | Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. ( Fraser, DM; McCowan, C; Sullivan, FM; Thompson, AM, 2014) |
| " Therefore, we examined the association between recent (1 year) prediagnostic use of aspirin (COX1/COX2 inhibitor), lymph node involvement at breast cancer diagnosis, and breast cancer-specific mortality." | 3.80 | Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study. ( Barron, TI; Bennett, K; Flahavan, EM; Sharp, L; Visvanathan, K, 2014) |
| "Four years ago, Michelle Holmes, Wendy Chen and collegues reported a significant negative correlation between aspirin use and breast cancer (Holmes et al." | 3.80 | "Frankly, my dear, I don't give a damn". ( Evans, RG, 2014) |
| "Recent evidence suggests that daily aspirin use decreases cancer risk, particularly for colorectal cancer, but evidence for alternate-day use is scant." | 3.79 | Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. ( Buring, JE; Cook, NR; Lee, IM; Moorthy, MV; Zhang, SM, 2013) |
| "From the Swedish Cancer Register, we identified patients diagnosed with colorectal, lung, prostate and breast cancers between 2006 and 2009 and matched them to the Swedish Prescribed Drug Register to obtain information on low-dose aspirin use prior to diagnosis." | 3.79 | Low-dose aspirin use and cancer characteristics: a population-based cohort study. ( Czene, K; Jonsson, F; Lundholm, C; Pawitan, Y; Smedby, KE; Yin, L, 2013) |
| "There is evidence that aspirin use reduces the risk of breast cancer." | 3.78 | The association between mammographic density measures and aspirin or other NSAID use. ( Apicella, C; Hopper, J; Stone, J; Treloar, S; Willenberg, L, 2012) |
| "The associations between use of aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen and breast cancer incidence in postmenopausal women are uncertain." | 3.78 | Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. ( Collins, LC; Hankinson, SE; Rosner, B; Smith-Warner, SA; Willett, WC; Zhang, X, 2012) |
| "The risk of developing breast cancer among patients taking both aspirin and an ACE inhibitor decreased as the ACE inhibitor dose increased." | 3.78 | Angiotensin-converting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer: a nationwide case-control study. ( Chen, PC; Guo, YL; Ho, WC; Lee, CH; Lee, HH; Lin, MH; Tsan, YT; Tseng, CD; Wang, JD, 2012) |
| "The purpose of this study is to investigate the combined effects of exemestane and aspirin on MCF-7 human breast cancer cells." | 3.78 | Synergistic effects of exemestane and aspirin on MCF-7 human breast cancer cells. ( Du, YY; Hu, LX; Pan, YY; Zhang, Y, 2012) |
| "We evaluated the relations of current use of aspirin, non-aspirin NSAIDs, and acetaminophen with breast cancer incidence in the Black Women's Health Study." | 3.77 | Regular aspirin use and breast cancer risk in US Black women. ( Boggs, DA; Bosco, JL; Hatch, EE; Palmer, JR; Rosenberg, L, 2011) |
| "Animal and in vitro studies suggest that aspirin may inhibit breast cancer metastasis." | 3.76 | Aspirin intake and survival after breast cancer. ( Chen, WY; Hankinson, SE; Hertzmark, E; Holmes, MD; Li, L; Spiegelman, D, 2010) |
| "Recent aspirin use was inversely associated with breast cancer risk (adjusted OR 0." | 3.76 | Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. ( Ambrosone, CB; Bonner, MR; Brasky, TM; Edge, SB; Freudenheim, JL; Kallakury, BV; Marian, C; Moysich, KB; Nie, J; Shields, PG; Tao, MH; Trevisan, M, 2010) |
| "The USPSTF recommends aspirin for the prevention of stroke and heart attack for those at risk, and screening for major depression and childhood obesity." | 3.76 | USPSTF recommendations you may have missed amid the breast cancer controversy. ( Campos-Outcalt, D, 2010) |
| "We assessed the associations for use of aspirin, other NSAIDs, and acetaminophen with breast cancer risk among premenopausal women in the prospective Nurses' Health Study II." | 3.75 | Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. ( Chen, WY; Eliassen, AH; Hankinson, SE; Hunter, DJ; Spiegelman, D; Willett, WC, 2009) |
| "The ability of aspirin to trigger apoptosis in cancer cells is well known and is consistent with the clinical and epidemiological evidence on its chemopreventive effects in curtailing epithelial cancers, including breast cancer." | 3.75 | Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. ( Abbruscato, TJ; Alfonso, LF; Arumugam, TV; Bhat, GJ; Srivenugopal, KS; Weidanz, JA, 2009) |
| "From 2000 to 2002, mailed questionnaires were used to obtain information on aspirin, ibuprofen, and other NSAID use and subsequent breast cancer events." | 3.74 | NSAIDs and breast cancer recurrence in a prospective cohort study. ( Caan, B; Habel, LA; Kwan, ML; Slattery, ML, 2007) |
| "In a monocentric prospective study, patients with stage II-IV breast cancer, who underwent CVC insertion for continuous infusional chemotherapy, were assigned to receive low-dose aspirin (100 mg daily)." | 3.74 | Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. ( Balduzzi, A; Cardillo, A; Colleoni, M; Curigliano, G; Dellapasqua, S; Ghisini, R; Goldhirsch, A; Lunghi, L; Orlando, L; Peruzzotti, G; Torrisi, R, 2007) |
| "Breast cancer risk was not significantly associated with NSAID use, but daily aspirin use was associated with a modest reduction in ER-positive breast cancer." | 3.74 | Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. ( Brinton, LA; Gierach, GL; Hollenbeck, AR; Lacey, JV; Leitzmann, MF; Richesson, D; Schatzkin, A, 2008) |
| "The effects of aspirin on sensitivity to TRAIL agonists and expression of apoptosis regulators was determined in human breast cancer cell lines and xenograft tumors." | 3.74 | Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. ( Bosman, J; Chen, F; Cryns, VL; Jordan, VC; Kwan, T; Lu, M; Strohecker, A, 2008) |
| "Use of nonsteroidal anti-inflammatory drugs (NSAIDs), particularly aspirin, has consistently been associated with reduced risk of breast cancer in case-control studies." | 3.73 | Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. ( Calle, EE; Connell, CJ; Feigelson, HS; Flanders, WD; Henley, SJ; Jacobs, EJ; Patel, AV; Rodriguez, C; Thun, MJ, 2005) |
| "Of the limited number of epidemiological investigations on aspirin (and other nonsteroidal anti-inflammatory drugs) and breast cancer, the majority observe a protective role, yet only a few report dose-response effects for frequency or duration of use." | 3.73 | Association of regular aspirin use and breast cancer risk. ( Menezes, RJ; Mirand, AL; Moysich, KB; Swede, H, 2005) |
| "Epidemiologic studies of the association between nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, and breast cancer risk have yielded inconsistent results." | 3.73 | Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. ( Anton-Culver, H; Bernstein, L; Deapen, D; Horn-Ross, PL; Marshall, SF; Mohrenweiser, H; Peel, D; Pinder, R; Purdie, DM; Reynolds, P; Ross, RK; Stram, D; West, D; Wright, WE; Ziogas, A, 2005) |
| "Women who use NSAIDs or doses of aspirin > 100 mg frequently may have a lower risk of breast cancer." | 3.73 | Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. ( Dasgupta, K; Ghosn, J; Hudson, M; Rahme, E; Rajan, R, 2005) |
| "We analyzed data from the prospective Women's Health Initiative (WHI) Observational Study to examine the effects of regular use of aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) on breast cancer risk." | 3.72 | Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. ( Anderson, G; Ascenseo, JL; Chlebowski, RT; Frid, DJ; Harris, RE; Jackson, RD; Loar, A; McTiernan, A; Rodabough, RJ; White, E, 2003) |
| "Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with a decrease in the risk of several cancers, including breast cancer." | 3.72 | Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. ( Britton, JA; Dannenberg, AJ; Gammon, MD; Neugut, AI; Subbaramaiah, K; Tawfik, H; Teitelbaum, SL; Terry, MB; Zhang, FF, 2004) |
| "Previous epidemiological studies have suggested that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with reduced risk of breast cancer, but some studies have been limited in their ability to separate the effects of aspirin from other NSAIDs or to account for breast cancer risk factors." | 3.71 | Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. ( Anderson, KE; Folsom, AR; Johnson, TW; Lazovich, D, 2002) |
| "Tamoxifen is the anti-estrogen the most widely used in breast cancer." | 3.69 | [Thromboembolic accidents in postmenopausal patients with adjuvant treatment by tamoxifen. Frequency, risk factors and prevention possibilities]. ( Abecassis, J; Cutuli, B; Fricker, JP; Petit, JC; Schumacher, C; Velten, M, 1995) |
| "We analyzed data from the prospective Nurses' Health Study to evaluate the influence of aspirin use on breast cancer risk." | 3.69 | Prospective study of regular aspirin use and the risk of breast cancer. ( Colditz, GA; Egan, KM; Giovannucci, E; Rosner, BA; Stampfer, MJ, 1996) |
| "Osteolysis effected in vitro by breast carcinomas can be inhibited by aspirin." | 3.65 | Human breast tumour-induced osteolysis and prostaglandins. ( Dowsett, M; Easty, DM; Easty, GC; Neville, AM; Powles, TJ, 1976) |
| " We therefore assessed the effect of Indomethacin and aspirin on some parameters of calcium metabolism in patients with breast cancer." | 3.65 | Failure of indomethacin to reduce hypercalcemia in patients with breast cancer. ( Bondy, PK; Coombes, RC; Neville, AM; Powles, TJ, 1976) |
| " This study aimed to assess the relationship between aspirin use and BC risk, and to determine if there is a dose-response relationship between aspirin and BC risk." | 3.01 | Prophylactic aspirin intake and breast cancer risk; A systematic review and meta-analysis of observational cohort studies. ( Bakierzynska, M; Corrigan, M; Cullinane, MC; Redmond, HP, 2023) |
| "Aspirin could reduce the risk of cancer metastasis." | 2.87 | The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. ( Chen, Y; Hu, X; Lv, Y; Lv, Z; Ni, C; Weng, X; Xia, W; Xin, Y; Xu, Q; Yang, L; Yuan, H; Zhang, W, 2018) |
| "Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four parallel cohorts." | 2.82 | ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. ( Berkman, L; Cafferty, FH; Cameron, D; Coyle, C; Gilbert, D; Gupta, S; Kynaston, H; Langley, RE; MacKenzie, M; Pramesh, CS; Ring, A; Rowley, S; Wilson, RH, 2016) |
| "Aspirin use was also inversely associated with coronary heart disease mortality (multivariable-adjusted RR = 0." | 2.73 | Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. ( Anderson, K; Bardia, A; Cerhan, JR; Ebbert, JO; Limburg, PJ; Olson, JE; Vachon, CM; Vierkant, RA; Wang, AH, 2007) |
| "Breast cancer is the most ubiquitous type of neoplasms among women worldwide." | 2.66 | Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions. ( Manoharan, R; Natarajan, SR; Ponnusamy, L; Thangaraj, K, 2020) |
| "Breast cancer has led the way and endocrine agents used to treat it-notably tamoxifen and the aromatase inhibitors-have now been shown to have a substantial preventive effect as well." | 2.58 | Progress in preventive therapy for cancer: a reminiscence and personal viewpoint. ( Cuzick, J, 2018) |
| "Aspirin has been incorporated into clinical practice for over 100 years at a low cost, making it particularly attractive as a potential agent in breast cancer prevention and as an adjunct treatment to endocrine therapy in the prophylaxis of cardiovascular complications." | 2.58 | Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review. ( Jorge, AJL; Leite, AM; Macedo, AVS; Martins, WA, 2018) |
| "Despite advances in breast cancer treatment, mortality from breast cancer is still high." | 2.52 | Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review. ( Ch Yiannakopoulou, E, 2015) |
| "Breast cancer is the most common cancer in women worldwide." | 2.52 | Update on breast cancer risk prediction and prevention. ( Cuzick, J; Sestak, I, 2015) |
| "Breast cancer is a neoplasm with the highest incidence and mortality rate among young women worldwide." | 2.50 | Clinical evidence of the relationship between aspirin and breast cancer risk (review). ( Camacho-Zavala, E; García-Castillo, V; González, GF; Jacobo-Herrera, NJ; Pérez-Plasencia, C; Urrutia, EL; Zentella-Dehesa, A, 2014) |
| "In the model estrogen-independent breast cancer, lunasin and aspirin administration inhibits cell proliferation, arrest cell cycle in S-phase as well as a decreases expression of cancer genes." | 2.50 | [Lunasin--a novel chemopreventive peptide]. ( Kuźmicz, I; Markowska, A; Wołosik, K, 2014) |
| "A slight reduction of breast cancer by taking aspirin and ibuprofen was both observed with pooled RR of 0." | 2.45 | Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. ( Hu, FL; Li, DD; Li, X; Li, XW; Wang, F; Zhang, WC; Zhao, YS; Zhu, S, 2009) |
| "Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants." | 2.45 | Aspirin, salicylates, and cancer. ( Duthie, GG; Elwood, PC; Gallagher, AM; Morgan, G; Mur, LA, 2009) |
| " There are now more than 15 epidemiological (case-control and cohort) studies indicating that long-term use of aspirin is associated with a reduced risk of colorectal cancer." | 2.41 | Aspirin and cancer risk: an update to 2001. ( Bosetti, C; Gallus, S; La Vecchia, C, 2002) |
| "10]), compared with never use, and there was no evidence of a dose-response relation." | 1.91 | Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study. ( Cairat, M; Dossus, L; Fournier, A; Hicks, B; Olesen, M; Pottegård, A, 2023) |
| "Globally, breast cancer is among the most frequently diagnosed and common cause of death among women." | 1.91 | Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail. ( Arnachellen, D; Augustine, TN; Pillay, K; Xulu, KR, 2023) |
| "Platelets also promoted cancer cell invasion in vitro." | 1.56 | Platelets disrupt vasculogenic mimicry by cancer cells. ( Bonder, CS; Cockshell, MP; Dale, BJ; Ebert, LM; Hyslop, SR; Josefsson, EC; Martini, C; Thompson, EJ; Woods, AE, 2020) |
| " ASA treatment also evoked an increase in platelet and granulocyte counts and decreased systemic NO bioavailability along with increased markers of systemic oxidant stress such as higher GSSG/lower GSH concentrations in RBC." | 1.56 | Unexpected effects of long-term treatment with acetylsalicylic acid on late phase of pulmonary metastasis in murine model of orthotopic breast cancer. ( Berkowicz, P; Chlopicki, S; Derszniak, K; Jasztal, A; Kieronska-Rudek, A; Kij, A; Matyjaszczyk-Gwarda, K; Proniewski, B; Przyborowski, K; Smeda, M; Sternak, M; Stojak, M, 2020) |
| "Aspirin treatment modified metabolites involved in suppressing lipogenesis, oxidative stress, and neoplastic formation." | 1.56 | Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth. ( Chiu, HH; Hsieh, CC; Kuo, CH; Wang, CH, 2020) |
| "Of note, patients with breast cancer receiving aspirin had lower circulating IL-8, and their platelets did not increase tumor cell invasion compared with patients not receiving aspirin." | 1.51 | Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis. ( Battinelli, EM; Ceglowski, JR; Chen, WY; El-Husayni, S; Forward, JA; Italiano, JE; Johnson, KE; Kulenthirarajan, R; Machlus, KR; Malloy, MW; Roweth, HG; Tippy, MD, 2019) |
| "The effect of chronic use of low-dose aspirin (LDA) on overall cancer is still unclear owing to many controversial results and methodological limitations of studies." | 1.51 | Reduced risk of cancer among low-dose aspirin users: Data from French health care databases. ( Ajrouche, A; Dalichampt, M; De Rycke, Y; Estellat, C; Hulot, JS; Messika Zeitoun, D; Tubach, F, 2019) |
| "Background Breast cancer is highly prevalent among women worldwide." | 1.48 | Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. ( Amaral, MEA; Campos, MM; de Azevedo Junior, WF; Leite, CE; Nery, LR, 2018) |
| "Ibuprofen was not effective in the comet assay but showed a significant reduction in MN frequency, with the nano formulation being more effective." | 1.48 | Aspirin and ibuprofen, in bulk and nanoforms: Effects on DNA damage in peripheral lymphocytes from breast cancer patients and healthy individuals. ( Anderson, D; Baumgartner, A; Dandah, O; Isreb, M; Linforth, R; Najafzadeh, M; Tait, C, 2018) |
| " GA enhanced the survival of EAC-bearing mice at a dosage of 0." | 1.48 | From epidemiology to treatment: Aspirin's prevention of brain and breast-cancer and cardioprotection may associate with its metabolite gentisic acid. ( Altinoz, MA; Cengiz, S; Elmaci, I; Emekli-Alturfan, E; Ozpinar, A, 2018) |
| "Aspirin treatment significantly inhibited the proliferation of 4T1 cells, and decreased the production of MCP-1 and PAI-1 in both the Ad-CM model and co-culture system." | 1.43 | Aspirin Breaks the Crosstalk between 3T3-L1 Adipocytes and 4T1 Breast Cancer Cells by Regulating Cytokine Production. ( Hsieh, CC; Huang, YS, 2016) |
| "Treatment with aspirin prior to chemotherapy suppressed the acquisition of chemoresistance by perturbing the nuclear translocation of NFκB in preexisting CSCs." | 1.43 | Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFκB-IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells. ( Das, T; De, S; Jana, D; Kajal, K; Khan, P; Manna, A; Mazumdar, M; Mukherjee, S; Saha, S; Sarkar, DK, 2016) |
| " Optimum type and dosage of NSAID for this purpose remains unclear." | 1.43 | Do postoperative NSAIDs improve breast cancer outcomes? A Best Evidence Topic. ( Lambert, K; McGlone, E; Sutton, L, 2016) |
| "Estrogen receptor negative (ER(-)) breast cancer is aggressive, responds poorly to current treatments and has a poor prognosis." | 1.42 | Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. ( Chattopadhyay, M; Kashfi, K; Kodela, R; Nath, N; Nazarenko, A; Rodes, DB, 2015) |
| "Efficacy of PA-2 was evaluated in human breast cancer cells in vitro, and in orthotopic and subcutaneous TNBC xenografts in nude mice." | 1.40 | Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. ( Alston, N; Cheng, KW; Huang, L; Mackenzie, GG; Ouyang, N; Rigas, B; Sun, Y; Vrankova, K; Wong, CC, 2014) |
| "Associations with breast cancer-specific mortality differed by IA ancestry; SOCS1 rs193779, STAT3 rs1026916, and STAT4 rs11685878 associations were limited to women with low IA ancestry, and associations with JAK1 rs2780890, rs2254002, and rs310245 and STAT1 rs11887698 were observed among women with high IA ancestry." | 1.40 | Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study. ( Hines, LM; John, EM; Lundgreen, A; Slattery, ML; Stern, MC; Torres-Mejia, G; Wolff, RK, 2014) |
| "Incident breast cancer cases were confirmed by medical record review." | 1.39 | Migraine and subsequent risk of breast cancer: a prospective cohort study. ( Buring, JE; Kurth, T; Lee, IM; Rexrode, KM; Tamimi, RM; Winter, AC, 2013) |
| "Aspirin has been reported to trigger apoptosis in various cancer cell lines." | 1.39 | Direct regulation of caspase‑3 by the transcription factor AP‑2α is involved in aspirin‑induced apoptosis in MDA‑MB‑453 breast cancer cells. ( Ding, X; He, Q; Hu, X; Li, L; Li, W; Wei, K; Xiang, S; Yan, F; Zhang, J; Zhong, Y, 2013) |
| "Berberine is an isoquinoline alkaloid that has several pharmacological effects such as antiinflammatory, antimicrobial, apoptosis-inducing and anticancer effects." | 1.38 | COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line. ( Ahmadian, S; Javadifar, N; Pazhang, Y; Shafiezadeh, M, 2012) |
| "In murine breast cancer models, the two interferon-gamma (IFN-γ) inducible chemokines and CXC-chemokine receptor 3 (CXCR3) receptor ligands, monokine induced by γ-interferon (CXCL9) and interferon-γ-inducible protein-10 (CXCL10) impair tumor growth and metastasis formation through recruitment of natural killer (NK) cells and tumor-suppressive T lymphocytes." | 1.38 | Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. ( Avril, S; Bronger, H; Cerny, C; Kiechle, M; Kraeft, S; Schmitt, M; Schwarz-Boeger, U; Stöckel, A, 2012) |
| "Through 2005, 1,581 incident breast cancer cases were observed." | 1.37 | Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. ( Anderson, KE; Bardia, A; Cerhan, JR; Lazovich, D; Limburg, PJ; Olson, JE; Vachon, CM; Vierkant, RA; Wang, AH, 2011) |
| "In support of this, the breast cancer cell line MCF-7 stimulated secretion of VEGF and a pro-angiogenic releasate from platelets." | 1.37 | Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. ( Battinelli, EM; Italiano, JE; Markens, BA, 2011) |
| "Aspirin and NSAIDs inhibit COX-2." | 1.37 | COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. ( Chen, WY; Colditz, GA; Collins, L; Hankinson, SE; Holmes, MD; Schnitt, SJ; Tamimi, RM, 2011) |
| "Breast cancer is one of the most common tumors in women of Western countries." | 1.36 | Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. ( de Lumen, BO; Hernández-Ledesma, B; Hsieh, CC, 2010) |
| "The occurrence of metastasis was ascertained monthly by a qualified oncologist, and confirmed, if necessary, by biopsy." | 1.36 | Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected]. ( Bhattacharyya, M; Chakraborty, S; Ghosh, R; Girish, GV; Sinha, AK, 2010) |
| "Detailed information on breast cancer incidence and tumour characteristics was obtained from nationwide health registers." | 1.35 | Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. ( Blot, WJ; Cronin-Fenton, DP; Friis, S; McLaughlin, JK; Olsen, JH; Overvad, K; Sørensen, HT; Thomassen, L; Tjønneland, A; Vogel, U, 2008) |
| "We also evaluate breast cancer associations with aspirin and nonsteroidal anti-inflammatory drugs." | 1.34 | IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. ( Baumgartner, KB; Baumgartner, R; Byers, T; Curtin, K; Giuliano, AR; Slattery, ML; Sweeney, C; Wolff, RR, 2007) |
| "Incident invasive cases of breast cancer from the Multiethnic Cohort (African Americans, Caucasians, Japanese Americans, Latinas, and Native Hawaiians from Hawaii and California) were identified from 1993 to 2002." | 1.34 | Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. ( Gill, JK; Henderson, BE; Kolonel, LN; Maskarinec, G; Pike, MC; Wilkens, LR, 2007) |
| "Maspin, an anti breast cancer protein, is produced in the normal mammary cells but not in malignant cells in breast cancer." | 1.33 | Restoration by aspirin of impaired plasma maspin level in human breast cancer. ( Bhattacharya, G; Chakraborty, K; Girish, GV; Kahn, NN; Sinha, AK; Sinha, N, 2006) |
| "We used human breast cancer (MCF-7) cells that are poorly metastatic but show highly inducible migration to determine bone-derived factors that induce migration of initially non-disseminating breast cancer cells." | 1.32 | Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells. ( Beckedorf, A; Bieberich, E; Silva, J, 2003) |
| "bFGF reduced apoptosis in MCF-7 breast cancer cells and up-regulated the expression of mitocondrial Bcl-2, whereas COX inhibitors meloxicam (selective COX-2) and aspirin (non-selective), induced apoptosis." | 1.32 | COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells. ( Foley, DA; Hill, AK; McDermott, EW; O'Higgins, NJ; Teh, SH; Young, LS, 2004) |
| "Among these breast cancers those that are estrogen-responsive respond well to existing therapeutic regimens while estrogen non-responsive cancers metastasize widely, demonstrate a high relapse rate, and respond poorly to therapy." | 1.31 | Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. ( Cakir, Y; Plummer, HK; Schuller, HM; Tithof, PK, 2002) |
| "Aspirin use was protective for colorectal cancer (odds ratio, 0." | 1.30 | Association between coronary heart disease and cancers of the breast, prostate, and colon. ( Ahsan, H; Chen, L; Hagan, M; Jacobson, JS; Khan, ZR; Neugut, AI; Pablos-Mendez, A; Rahman, MI; Rosenberg, DJ; Shea, S; Wahid, N, 1998) |
| "The relative risk of breast cancer was reduced in women using these compounds at least 3 times per week for > or = 1 year [odds ratio (OR) = 0." | 1.29 | Nonsteroidal antiinflammatory drugs and breast cancer. ( Farrar, WB; Harris, RE; Namboodiri, KK, 1996) |
| "23 (60%) of 38 human breast carcinomas had significant in-vitro osteolytic activity." | 1.26 | Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. ( Dowsett, M; Easty, DM; Easty, GC; Neville, AM; Powles, TJ, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (5.22) | 18.7374 |
| 1990's | 16 (6.96) | 18.2507 |
| 2000's | 52 (22.61) | 29.6817 |
| 2010's | 116 (50.43) | 24.3611 |
| 2020's | 34 (14.78) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 2 |
| Zhou, J | 1 |
| Zhang, T | 1 |
| Zhu, H | 1 |
| Qian, H | 1 |
| Zhang, H | 3 |
| Huang, W | 1 |
| Gust, R | 1 |
| Xu, R | 1 |
| Yan, Y | 1 |
| Zheng, X | 1 |
| Chen, W | 1 |
| Li, H | 1 |
| Dong, Z | 1 |
| Milani, D | 1 |
| Khorramymehr, S | 1 |
| Vasaghi-Gharamaleki, B | 1 |
| Acheampong, T | 1 |
| Lee Argov, EJ | 1 |
| Terry, MB | 6 |
| Rodriguez, CB | 1 |
| Agovino, M | 1 |
| Wei, Y | 1 |
| Athilat, S | 1 |
| Tehranifar, P | 1 |
| Rezania, MA | 1 |
| Eghtedari, A | 1 |
| Taha, MF | 1 |
| Ardekani, AM | 1 |
| Javeri, A | 1 |
| Ramos-Inza, S | 1 |
| Encío, I | 1 |
| Raza, A | 1 |
| Sharma, AK | 1 |
| Sanmartín, C | 1 |
| Plano, D | 1 |
| Li, Y | 1 |
| He, X | 1 |
| Lu, X | 1 |
| Gong, Z | 1 |
| Li, Q | 2 |
| Zhang, L | 1 |
| Yang, R | 1 |
| Wu, C | 1 |
| Huang, J | 1 |
| Ding, J | 1 |
| He, Y | 1 |
| Chen, C | 1 |
| Cao, B | 1 |
| Zhou, D | 1 |
| Shi, Y | 1 |
| Chen, J | 2 |
| Wang, C | 1 |
| Zhang, S | 1 |
| Zhang, J | 4 |
| Ye, J | 2 |
| You, H | 1 |
| Cairat, M | 3 |
| Pottegård, A | 1 |
| Olesen, M | 1 |
| Dossus, L | 3 |
| Fournier, A | 3 |
| Hicks, B | 1 |
| Thakur, B | 3 |
| Saha, L | 3 |
| Dahiya, D | 3 |
| Bhatia, A | 3 |
| Yaghjyan, L | 3 |
| Eliassen, AH | 4 |
| Colditz, G | 3 |
| Rosner, B | 4 |
| Schedin, P | 2 |
| Wijayabahu, A | 3 |
| Tamimi, RM | 5 |
| Yang, YS | 2 |
| Kornelius, E | 2 |
| Lo, SC | 2 |
| Wang, YH | 1 |
| Huang, CN | 2 |
| Løfling, L | 1 |
| Støer, NC | 2 |
| Nafisi, S | 1 |
| Ursin, G | 2 |
| Hofvind, S | 1 |
| Botteri, E | 2 |
| Liu, FC | 1 |
| Miller, TJ | 1 |
| Henn, D | 1 |
| Nguyen, D | 1 |
| Momeni, A | 1 |
| Bakierzynska, M | 1 |
| Cullinane, MC | 1 |
| Redmond, HP | 1 |
| Corrigan, M | 1 |
| Löfling, LL | 1 |
| Andreassen, BK | 1 |
| Arnachellen, D | 1 |
| Xulu, KR | 2 |
| Pillay, K | 1 |
| Augustine, TN | 2 |
| Lai, SW | 1 |
| Hwang, BF | 1 |
| Liu, CS | 1 |
| Liao, KF | 1 |
| Malecki, KMC | 1 |
| Wang, T | 4 |
| McCullough, LE | 1 |
| White, AJ | 1 |
| Bradshaw, PT | 2 |
| Xu, X | 1 |
| Cho, YH | 1 |
| Teitelbaum, SL | 4 |
| Neugut, AI | 6 |
| Santella, RM | 2 |
| Gammon, MD | 4 |
| Joharatnam-Hogan, N | 1 |
| Cafferty, F | 1 |
| Hubner, R | 1 |
| Swinson, D | 1 |
| Sothi, S | 1 |
| Gupta, K | 1 |
| Falk, S | 1 |
| Patel, K | 1 |
| Warner, N | 1 |
| Kunene, V | 1 |
| Rowley, S | 2 |
| Khabra, K | 1 |
| Underwood, T | 1 |
| Jankowski, J | 2 |
| Bridgewater, J | 1 |
| Crossley, A | 1 |
| Henson, V | 1 |
| Berkman, L | 2 |
| Gilbert, D | 2 |
| Kynaston, H | 2 |
| Ring, A | 2 |
| Cameron, D | 2 |
| Din, F | 1 |
| Graham, J | 1 |
| Iveson, T | 1 |
| Adams, R | 1 |
| Thomas, A | 1 |
| Wilson, R | 1 |
| Pramesh, CS | 2 |
| Langley, R | 1 |
| Tran, PHL | 2 |
| Yin, W | 2 |
| Tran, TTD | 2 |
| Nguyen, TNG | 2 |
| Lee, BJ | 2 |
| Duan, W | 2 |
| Zhu, X | 1 |
| Yang, J | 1 |
| Zhang, E | 1 |
| Qiao, W | 1 |
| Li, X | 2 |
| Wu, Y | 3 |
| Yan, B | 1 |
| Xu, W | 1 |
| Guo, L | 1 |
| Wang, Z | 3 |
| Li, G | 1 |
| Hou, N | 1 |
| Ling, R | 2 |
| Martini, C | 1 |
| Thompson, EJ | 1 |
| Hyslop, SR | 1 |
| Cockshell, MP | 1 |
| Dale, BJ | 1 |
| Ebert, LM | 1 |
| Woods, AE | 1 |
| Josefsson, EC | 1 |
| Bonder, CS | 1 |
| Smeda, M | 1 |
| Kij, A | 1 |
| Proniewski, B | 1 |
| Matyjaszczyk-Gwarda, K | 1 |
| Przyborowski, K | 1 |
| Jasztal, A | 1 |
| Derszniak, K | 1 |
| Berkowicz, P | 1 |
| Kieronska-Rudek, A | 1 |
| Stojak, M | 1 |
| Sternak, M | 1 |
| Chlopicki, S | 1 |
| McCarthy, AM | 1 |
| Kumar, NP | 1 |
| He, W | 1 |
| Regan, S | 1 |
| Welch, M | 1 |
| Moy, B | 1 |
| Iafrate, AJ | 1 |
| Chan, AT | 1 |
| Bardia, A | 4 |
| Armstrong, K | 1 |
| Ponnusamy, L | 1 |
| Natarajan, SR | 1 |
| Thangaraj, K | 1 |
| Manoharan, R | 1 |
| Sambi, M | 1 |
| Samuel, V | 1 |
| Qorri, B | 1 |
| Haq, S | 1 |
| Burov, SV | 1 |
| Markvicheva, E | 1 |
| Harless, W | 1 |
| Szewczuk, MR | 1 |
| Hsieh, CC | 3 |
| Chiu, HH | 1 |
| Wang, CH | 1 |
| Kuo, CH | 1 |
| Bertrand, KA | 1 |
| Bethea, TN | 1 |
| Gerlovin, H | 1 |
| Coogan, PF | 1 |
| Barber, L | 1 |
| Rosenberg, L | 3 |
| Palmer, JR | 2 |
| Cao, Y | 1 |
| Tan, A | 1 |
| Zhang, W | 2 |
| Xia, L | 1 |
| Ren, X | 1 |
| Cui, M | 1 |
| Liu, T | 1 |
| Ling, C | 1 |
| Xu, Y | 1 |
| Deng, D | 1 |
| Zhang, X | 4 |
| Gu, Y | 1 |
| Wang, P | 1 |
| Bhattacharya, A | 1 |
| Mukherjee, S | 3 |
| Khan, P | 2 |
| Banerjee, S | 2 |
| Dutta, A | 2 |
| Banerjee, N | 1 |
| Sengupta, D | 1 |
| Basak, U | 1 |
| Chakraborty, S | 2 |
| Chattopadhyay, S | 1 |
| Jana, K | 1 |
| Sarkar, DK | 2 |
| Chatterjee, S | 1 |
| Das, T | 2 |
| Al Rahmoun, M | 2 |
| Gunter, MJ | 2 |
| Severi, G | 2 |
| Ge, X | 1 |
| Li, Z | 1 |
| Su, L | 1 |
| Yang, H | 1 |
| Song, J | 1 |
| Ma, S | 1 |
| Guo, C | 1 |
| Sun, C | 1 |
| Han, T | 1 |
| Qu, G | 1 |
| Jiang, Y | 1 |
| Zhou, Q | 1 |
| Sun, Y | 2 |
| Liu, J | 2 |
| Zheng, F | 1 |
| Yang, M | 2 |
| Wu, X | 1 |
| Liu, A | 1 |
| Cheng, R | 1 |
| Liu, YJ | 1 |
| Cui, JW | 1 |
| Liu, XL | 1 |
| Li, P | 1 |
| Zhu, LZ | 1 |
| Lu, SY | 1 |
| Zou, L | 1 |
| Wu, XQ | 1 |
| Li, YX | 1 |
| Zhou, Y | 2 |
| Fang, ZY | 1 |
| Wei, W | 1 |
| Lu, L | 1 |
| Shi, L | 1 |
| Zeng, J | 1 |
| Wen, Z | 1 |
| Clarke, CA | 1 |
| Canchola, AJ | 1 |
| Moy, LM | 1 |
| Neuhausen, SL | 1 |
| Chung, NT | 1 |
| Lacey, JV | 2 |
| Bernstein, L | 2 |
| Chiou, JY | 1 |
| Lai, YR | 1 |
| Peng, CH | 1 |
| Chen, WY | 7 |
| Holmes, MD | 6 |
| Murphy, L | 1 |
| Brown, C | 2 |
| Smith, A | 1 |
| Cranfield, F | 1 |
| Sharp, L | 3 |
| Visvanathan, K | 3 |
| Bennett, K | 3 |
| Barron, TI | 4 |
| Altundag, K | 3 |
| Kong, J | 1 |
| Cronin-Fenton, D | 3 |
| Lash, TL | 2 |
| Ahern, TP | 2 |
| Damkier, P | 1 |
| Christiansen, P | 2 |
| Ejlertsen, B | 3 |
| Sørensen, HT | 3 |
| Yang, L | 1 |
| Lv, Z | 1 |
| Xia, W | 1 |
| Xin, Y | 1 |
| Yuan, H | 1 |
| Chen, Y | 1 |
| Hu, X | 2 |
| Lv, Y | 1 |
| Xu, Q | 1 |
| Weng, X | 1 |
| Ni, C | 1 |
| Thomsen, AML | 1 |
| Pedersen, AB | 1 |
| Kristensen, NR | 1 |
| Møller, BK | 1 |
| Erikstrup, C | 1 |
| Christiansen, PM | 1 |
| Nørgaard, M | 1 |
| Zhao, M | 1 |
| Wang, Y | 1 |
| Du, C | 1 |
| Liu, Y | 1 |
| Zhang, N | 1 |
| Luo, F | 2 |
| Amaral, MEA | 1 |
| Nery, LR | 1 |
| Leite, CE | 1 |
| de Azevedo Junior, WF | 1 |
| Campos, MM | 1 |
| Dandah, O | 1 |
| Najafzadeh, M | 1 |
| Isreb, M | 1 |
| Linforth, R | 1 |
| Tait, C | 1 |
| Baumgartner, A | 1 |
| Anderson, D | 1 |
| Ebell, MH | 1 |
| Parada, H | 1 |
| McClain, KM | 1 |
| Hawk, E | 1 |
| Maresso, KC | 1 |
| Brown, P | 1 |
| Cuzick, J | 3 |
| Zarà, M | 1 |
| Canobbio, I | 1 |
| Visconte, C | 1 |
| Canino, J | 1 |
| Torti, M | 1 |
| Guidetti, GF | 1 |
| Jeon, HL | 1 |
| Jeong, S | 1 |
| Shin, JY | 1 |
| Altinoz, MA | 2 |
| Elmaci, I | 1 |
| Cengiz, S | 1 |
| Emekli-Alturfan, E | 1 |
| Ozpinar, A | 1 |
| Usman, MW | 1 |
| Gao, J | 1 |
| Zheng, T | 1 |
| Rui, C | 1 |
| Li, T | 1 |
| Bian, X | 1 |
| Cheng, H | 1 |
| Liu, P | 1 |
| Williams, AD | 1 |
| Li, YR | 1 |
| So, A | 1 |
| Steel, L | 1 |
| Carrigan, E | 1 |
| Ro, V | 1 |
| Nguyen, J | 1 |
| Tchou, J | 1 |
| Leite, AM | 1 |
| Macedo, AVS | 1 |
| Jorge, AJL | 1 |
| Martins, WA | 1 |
| Jawahar, A | 1 |
| Nagamine, A | 1 |
| Gamez, R | 1 |
| Bens, A | 1 |
| Friis, S | 2 |
| Dehlendorff, C | 1 |
| Jensen, MB | 1 |
| Kroman, N | 1 |
| Mellemkjær, L | 1 |
| Frisk, G | 1 |
| Ekberg, S | 1 |
| Lidbrink, E | 1 |
| Eloranta, S | 1 |
| Sund, M | 1 |
| Fredriksson, I | 1 |
| Lambe, M | 1 |
| Smedby, KE | 3 |
| Johnson, KE | 1 |
| Ceglowski, JR | 1 |
| Roweth, HG | 1 |
| Forward, JA | 1 |
| Tippy, MD | 1 |
| El-Husayni, S | 1 |
| Kulenthirarajan, R | 1 |
| Malloy, MW | 1 |
| Machlus, KR | 1 |
| Italiano, JE | 2 |
| Battinelli, EM | 2 |
| Kehm, RD | 1 |
| Hopper, JL | 1 |
| John, EM | 2 |
| Phillips, KA | 1 |
| MacInnis, RJ | 1 |
| Dite, GS | 1 |
| Milne, RL | 1 |
| Liao, Y | 1 |
| Zeinomar, N | 1 |
| Knight, JA | 1 |
| Southey, MC | 1 |
| Vahdat, L | 1 |
| Kornhauser, N | 1 |
| Cigler, T | 1 |
| Chung, WK | 1 |
| Giles, GG | 1 |
| McLachlan, SA | 1 |
| Friedlander, ML | 1 |
| Weideman, PC | 1 |
| Glendon, G | 1 |
| Nesci, S | 1 |
| Andrulis, IL | 1 |
| Buys, SS | 1 |
| Daly, MB | 1 |
| Talaiezadeh, A | 1 |
| Papan, AM | 1 |
| Nazari, P | 1 |
| Mousavi Ghanavati, SP | 1 |
| Ramazani, A | 1 |
| Barua, HT | 1 |
| Zhang, Y | 2 |
| Midge, SB | 1 |
| Simmons, J | 1 |
| Jordan, CD | 1 |
| Sonbol, MB | 1 |
| Maihle, N | 1 |
| Tang, SC | 1 |
| Ajrouche, A | 1 |
| De Rycke, Y | 1 |
| Dalichampt, M | 1 |
| Messika Zeitoun, D | 1 |
| Hulot, JS | 1 |
| Estellat, C | 1 |
| Tubach, F | 1 |
| Hankinson, SE | 5 |
| Feskanich, D | 1 |
| Cook, NR | 2 |
| Lee, IM | 4 |
| Zhang, SM | 3 |
| Moorthy, MV | 1 |
| Buring, JE | 4 |
| Jonsson, F | 1 |
| Yin, L | 1 |
| Lundholm, C | 2 |
| Czene, K | 1 |
| Pawitan, Y | 2 |
| Holmes, CE | 2 |
| Jasielec, J | 1 |
| Levis, JE | 1 |
| Skelly, J | 1 |
| Muss, HB | 2 |
| Shai, A | 1 |
| Rennert, HS | 1 |
| Lavie, O | 1 |
| Ballan-Haj, M | 1 |
| Bitterman, A | 1 |
| Steiner, M | 1 |
| Keren, S | 1 |
| Rennert, G | 1 |
| Roop, RP | 1 |
| Naughton, MJ | 1 |
| Van Poznak, C | 1 |
| Schneider, JG | 1 |
| Lammers, PE | 1 |
| Pluard, TJ | 1 |
| Johnson, F | 1 |
| Eby, CS | 1 |
| Weilbaecher, KN | 1 |
| Ljung, R | 1 |
| Sennerstam, R | 1 |
| Mattsson, F | 1 |
| Auer, G | 1 |
| Lagergren, J | 1 |
| Huang, L | 2 |
| Wong, CC | 2 |
| Mackenzie, GG | 1 |
| Cheng, KW | 2 |
| Vrankova, K | 1 |
| Alston, N | 1 |
| Ouyang, N | 1 |
| Rigas, B | 2 |
| Murray, LJ | 2 |
| Cooper, JA | 1 |
| Hughes, CM | 2 |
| Powe, DG | 1 |
| Cardwell, CR | 2 |
| Olsson, H | 1 |
| Holm, J | 1 |
| Andersson, TM | 1 |
| Adami, HO | 2 |
| Askling, J | 1 |
| Wong, TY | 1 |
| Li, F | 1 |
| Lin, SM | 1 |
| Chan, FL | 1 |
| Chen, S | 1 |
| Leung, LK | 1 |
| Duggan, C | 1 |
| Wang, CY | 2 |
| Xiao, L | 2 |
| McTiernan, A | 3 |
| Jacobo-Herrera, NJ | 1 |
| Pérez-Plasencia, C | 1 |
| Camacho-Zavala, E | 1 |
| González, GF | 1 |
| Urrutia, EL | 1 |
| García-Castillo, V | 1 |
| Zentella-Dehesa, A | 1 |
| Fraser, DM | 1 |
| Sullivan, FM | 1 |
| Thompson, AM | 1 |
| McCowan, C | 1 |
| Wołosik, K | 1 |
| Markowska, A | 1 |
| Kuźmicz, I | 1 |
| Flahavan, EM | 1 |
| Slattery, ML | 3 |
| Lundgreen, A | 1 |
| Hines, LM | 1 |
| Torres-Mejia, G | 1 |
| Wolff, RK | 1 |
| Stern, MC | 1 |
| Yiannakopoulou, ECh | 1 |
| Ch Yiannakopoulou, E | 1 |
| Sestak, I | 1 |
| Evans, RG | 1 |
| Basudhar, D | 1 |
| Cheng, RC | 1 |
| Bharadwaj, G | 1 |
| Ridnour, LA | 1 |
| Wink, DA | 1 |
| Miranda, KM | 1 |
| Zhong, S | 2 |
| Chen, L | 3 |
| Ma, T | 1 |
| Tang, J | 2 |
| Zhao, J | 2 |
| Huang, XZ | 1 |
| Gao, P | 1 |
| Sun, JX | 1 |
| Song, YX | 1 |
| Tsai, CC | 1 |
| Chen, XW | 1 |
| Chen, P | 1 |
| Xu, HM | 1 |
| Wang, ZN | 1 |
| Murphy, LM | 1 |
| Maity, G | 1 |
| De, A | 1 |
| Das, A | 1 |
| Sarkar, S | 1 |
| Banerjee, SK | 1 |
| Lee, YR | 1 |
| Kim, KM | 1 |
| Jeon, BH | 1 |
| Choi, S | 1 |
| Nath, N | 3 |
| Chattopadhyay, M | 3 |
| Rodes, DB | 1 |
| Nazarenko, A | 1 |
| Kodela, R | 2 |
| Kashfi, K | 3 |
| Tunalı, NE | 1 |
| Yu, D | 1 |
| Kastrati, I | 2 |
| Litosh, VA | 1 |
| Zhao, S | 1 |
| Alvarez, M | 1 |
| Thatcher, GR | 2 |
| Frasor, J | 2 |
| Keenan, TE | 1 |
| Ebbert, JO | 2 |
| Lazovich, D | 3 |
| Wang, AH | 3 |
| Vierkant, RA | 3 |
| Olson, JE | 3 |
| Vachon, CM | 3 |
| Limburg, PJ | 3 |
| Anderson, KE | 4 |
| Cerhan, JR | 3 |
| Talarico, G | 1 |
| Orecchioni, S | 1 |
| Dallaglio, K | 1 |
| Reggiani, F | 1 |
| Mancuso, P | 1 |
| Calleri, A | 1 |
| Gregato, G | 1 |
| Labanca, V | 1 |
| Rossi, T | 1 |
| Noonan, DM | 1 |
| Albini, A | 1 |
| Bertolini, F | 1 |
| Huang, YS | 1 |
| Saha, S | 1 |
| Kajal, K | 1 |
| Mazumdar, M | 1 |
| Manna, A | 1 |
| De, S | 1 |
| Jana, D | 1 |
| Turturro, SB | 1 |
| Najor, MS | 1 |
| Ruby, CE | 1 |
| Cobleigh, MA | 1 |
| Abukhdeir, AM | 1 |
| Sutton, L | 1 |
| McGlone, E | 1 |
| Lambert, K | 1 |
| Cronin-Fenton, DP | 2 |
| Heide-Jørgensen, U | 1 |
| Bradley, MC | 1 |
| Black, A | 1 |
| Freedman, AN | 1 |
| Dirican, E | 1 |
| Vaughan, LE | 1 |
| Prizment, A | 1 |
| Blair, CK | 1 |
| Thomas, W | 1 |
| Coyle, C | 1 |
| Cafferty, FH | 1 |
| MacKenzie, M | 1 |
| Gupta, S | 1 |
| Wilson, RH | 1 |
| Langley, RE | 1 |
| Henry, WS | 1 |
| Laszewski, T | 1 |
| Tsang, T | 1 |
| Beca, F | 1 |
| Beck, AH | 1 |
| McAllister, SS | 1 |
| Toker, A | 1 |
| Shiao, J | 1 |
| Thomas, KM | 1 |
| Rahimi, AS | 1 |
| Rao, R | 1 |
| Yan, J | 1 |
| Xie, XJ | 1 |
| DaSilva, M | 1 |
| Spangler, A | 1 |
| Leitch, M | 1 |
| Wooldridge, R | 1 |
| Rivers, A | 1 |
| Farr, D | 1 |
| Haley, B | 1 |
| Kim, DW | 1 |
| Mc Menamin, ÚC | 1 |
| Wood, ME | 1 |
| Sprague, BL | 1 |
| Oustimov, A | 1 |
| Synnstvedt, MB | 1 |
| Cuke, M | 1 |
| Conant, EF | 1 |
| Kontos, D | 1 |
| Delgado-Rivera, L | 1 |
| Georgieva, G | 1 |
| Menamin, ÚM | 1 |
| Cardwell, C | 1 |
| Hughes, C | 1 |
| Murray, L | 1 |
| Takkouche, B | 1 |
| Regueira-Méndez, C | 1 |
| Etminan, M | 1 |
| Zhao, YS | 1 |
| Zhu, S | 1 |
| Li, XW | 1 |
| Wang, F | 1 |
| Hu, FL | 1 |
| Li, DD | 1 |
| Zhang, WC | 1 |
| Zhu, XG | 1 |
| Tao, L | 1 |
| Mei, ZR | 1 |
| Wu, HP | 1 |
| Jiang, ZW | 1 |
| Spiegelman, D | 2 |
| Willett, WC | 2 |
| Hunter, DJ | 1 |
| Alfonso, LF | 1 |
| Srivenugopal, KS | 1 |
| Arumugam, TV | 1 |
| Abbruscato, TJ | 1 |
| Weidanz, JA | 1 |
| Bhat, GJ | 1 |
| Elwood, PC | 1 |
| Gallagher, AM | 1 |
| Duthie, GG | 1 |
| Mur, LA | 1 |
| Morgan, G | 1 |
| Otto, F | 1 |
| Baron, JA | 2 |
| Brown, PH | 1 |
| Burn, J | 1 |
| Greenwald, P | 1 |
| La Vecchia, C | 2 |
| Meyskens, F | 1 |
| Senn, HJ | 1 |
| Thun, M | 1 |
| Sorensen, B | 1 |
| Buist, DS | 1 |
| Aiello Bowles, EJ | 1 |
| White, E | 2 |
| Rossing, MA | 1 |
| Potter, J | 1 |
| Urban, N | 1 |
| Vassell, R | 1 |
| Kogan, M | 1 |
| Li, L | 2 |
| Hertzmark, E | 1 |
| Bourdeanu, L | 1 |
| Luu, T | 1 |
| Hernández-Ledesma, B | 1 |
| de Lumen, BO | 1 |
| Brasky, TM | 3 |
| Bonner, MR | 3 |
| Moysich, KB | 4 |
| Ambrosone, CB | 3 |
| Nie, J | 3 |
| Tao, MH | 3 |
| Edge, SB | 3 |
| Kallakury, BV | 2 |
| Marian, C | 3 |
| Trevisan, M | 3 |
| Shields, PG | 3 |
| Freudenheim, JL | 3 |
| Campos-Outcalt, D | 1 |
| Ararat, E | 1 |
| Sahin, I | 1 |
| Bhattacharyya, M | 1 |
| Girish, GV | 3 |
| Ghosh, R | 1 |
| Sinha, AK | 3 |
| Ochs-Balcom, HM | 1 |
| Goerlitz, DS | 1 |
| Markens, BA | 1 |
| Schnitt, SJ | 1 |
| Collins, L | 1 |
| Colditz, GA | 2 |
| Bosco, JL | 1 |
| Boggs, DA | 1 |
| Hatch, EE | 1 |
| Luo, T | 1 |
| Yan, HM | 1 |
| He, P | 1 |
| Luo, Y | 1 |
| Yang, YF | 1 |
| Zheng, H | 1 |
| Stone, J | 1 |
| Willenberg, L | 1 |
| Apicella, C | 1 |
| Treloar, S | 1 |
| Hopper, J | 1 |
| Pazhang, Y | 1 |
| Ahmadian, S | 1 |
| Javadifar, N | 1 |
| Shafiezadeh, M | 1 |
| Barsegian, A | 1 |
| Boring, D | 1 |
| Bronger, H | 1 |
| Kraeft, S | 1 |
| Schwarz-Boeger, U | 1 |
| Cerny, C | 1 |
| Stöckel, A | 1 |
| Avril, S | 1 |
| Kiechle, M | 1 |
| Schmitt, M | 1 |
| Smith-Warner, SA | 1 |
| Collins, LC | 1 |
| Hudis, CA | 1 |
| Subbaramaiah, K | 2 |
| Morris, PG | 1 |
| Dannenberg, AJ | 2 |
| Lee, HH | 1 |
| Tsan, YT | 1 |
| Ho, WC | 1 |
| Lin, MH | 1 |
| Lee, CH | 1 |
| Tseng, CD | 1 |
| Guo, YL | 1 |
| Wang, JD | 1 |
| Chen, PC | 1 |
| Winter, AC | 1 |
| Rexrode, KM | 1 |
| Kurth, T | 1 |
| Yan, F | 1 |
| He, Q | 1 |
| Li, W | 1 |
| Wei, K | 1 |
| Zhong, Y | 1 |
| Ding, X | 1 |
| Xiang, S | 1 |
| Hu, LX | 1 |
| Du, YY | 1 |
| Pan, YY | 1 |
| Bosetti, C | 1 |
| Gallus, S | 1 |
| Johnson, TW | 1 |
| Folsom, AR | 1 |
| Silva, J | 1 |
| Beckedorf, A | 1 |
| Bieberich, E | 1 |
| Robb-Nicholson, C | 1 |
| Harris, RE | 2 |
| Chlebowski, RT | 1 |
| Jackson, RD | 1 |
| Frid, DJ | 1 |
| Ascenseo, JL | 1 |
| Anderson, G | 1 |
| Loar, A | 1 |
| Rodabough, RJ | 1 |
| Teh, SH | 1 |
| Hill, AK | 1 |
| Foley, DA | 1 |
| McDermott, EW | 1 |
| O'Higgins, NJ | 1 |
| Young, LS | 1 |
| Zhang, FF | 1 |
| Tawfik, H | 1 |
| Britton, JA | 1 |
| DuBois, RN | 1 |
| Din, FV | 1 |
| Dunlop, MG | 1 |
| Stark, LA | 1 |
| García Rodríguez, LA | 1 |
| González-Pérez, A | 1 |
| Tait, CR | 1 |
| Moorman, PG | 1 |
| Woloshin, S | 1 |
| Schwartz, LM | 1 |
| Jacobs, EJ | 1 |
| Thun, MJ | 1 |
| Connell, CJ | 1 |
| Rodriguez, C | 1 |
| Henley, SJ | 1 |
| Feigelson, HS | 1 |
| Patel, AV | 1 |
| Flanders, WD | 1 |
| Calle, EE | 1 |
| Swede, H | 1 |
| Mirand, AL | 1 |
| Menezes, RJ | 1 |
| Marshall, SF | 1 |
| Anton-Culver, H | 1 |
| Deapen, D | 1 |
| Horn-Ross, PL | 1 |
| Mohrenweiser, H | 1 |
| Peel, D | 1 |
| Pinder, R | 1 |
| Purdie, DM | 1 |
| Reynolds, P | 1 |
| Stram, D | 1 |
| West, D | 1 |
| Wright, WE | 1 |
| Ziogas, A | 1 |
| Ross, RK | 1 |
| Hampton, T | 1 |
| Rahme, E | 1 |
| Ghosn, J | 1 |
| Dasgupta, K | 1 |
| Rajan, R | 1 |
| Hudson, M | 1 |
| Bhattacharya, G | 2 |
| Crew, KD | 1 |
| Lin, J | 1 |
| Ridker, PM | 1 |
| Rifai, N | 1 |
| Manson, JE | 2 |
| Sinha, N | 1 |
| Chakraborty, K | 1 |
| Kahn, NN | 1 |
| Shen, J | 1 |
| Kwan, ML | 1 |
| Habel, LA | 1 |
| Caan, B | 1 |
| Curtin, K | 1 |
| Baumgartner, R | 1 |
| Sweeney, C | 1 |
| Byers, T | 1 |
| Giuliano, AR | 1 |
| Baumgartner, KB | 1 |
| Wolff, RR | 1 |
| Anderson, K | 1 |
| Curigliano, G | 1 |
| Balduzzi, A | 1 |
| Cardillo, A | 1 |
| Ghisini, R | 1 |
| Peruzzotti, G | 1 |
| Orlando, L | 1 |
| Torrisi, R | 1 |
| Dellapasqua, S | 1 |
| Lunghi, L | 1 |
| Goldhirsch, A | 1 |
| Colleoni, M | 1 |
| Gill, JK | 1 |
| Maskarinec, G | 1 |
| Wilkens, LR | 1 |
| Pike, MC | 1 |
| Henderson, BE | 1 |
| Kolonel, LN | 1 |
| Mangiapane, S | 1 |
| Blettner, M | 1 |
| Schlattmann, P | 1 |
| Tassinari, D | 1 |
| Santelmo, C | 1 |
| Tombesi, P | 1 |
| Sartori, S | 1 |
| Robles-Díaz, G | 1 |
| Fastag, D | 1 |
| Thomassen, L | 1 |
| Tjønneland, A | 1 |
| Overvad, K | 1 |
| Vogel, U | 1 |
| McLaughlin, JK | 1 |
| Blot, WJ | 1 |
| Olsen, JH | 1 |
| Gierach, GL | 1 |
| Schatzkin, A | 1 |
| Leitzmann, MF | 1 |
| Richesson, D | 1 |
| Hollenbeck, AR | 1 |
| Brinton, LA | 1 |
| Huang, JC | 1 |
| Pace, TR | 1 |
| Howard, AB | 1 |
| Lu, M | 1 |
| Strohecker, A | 1 |
| Chen, F | 1 |
| Kwan, T | 1 |
| Bosman, J | 1 |
| Jordan, VC | 1 |
| Cryns, VL | 1 |
| Baluda, VP | 1 |
| Lukoianova, TI | 1 |
| Baluda, MV | 1 |
| Forti, RL | 1 |
| Mitchell, WM | 1 |
| Workman, RJ | 1 |
| Forbes, JT | 1 |
| Hubbard, WC | 1 |
| Powles, TJ | 6 |
| Dady, PJ | 1 |
| Williams, J | 1 |
| Easty, GC | 5 |
| Coombes, RC | 3 |
| Rolland, PH | 1 |
| Martin, PM | 1 |
| Bourry, M | 1 |
| Rolland, AM | 1 |
| Serment, H | 1 |
| Cutuli, B | 1 |
| Petit, JC | 1 |
| Fricker, JP | 1 |
| Schumacher, C | 1 |
| Velten, M | 1 |
| Abecassis, J | 1 |
| Schreinemachers, DM | 1 |
| Everson, RB | 1 |
| Peto, R | 1 |
| Collins, R | 1 |
| Gray, R | 1 |
| Egan, KM | 1 |
| Stampfer, MJ | 1 |
| Giovannucci, E | 1 |
| Rosner, BA | 1 |
| Namboodiri, KK | 1 |
| Farrar, WB | 1 |
| Olivotto, IA | 2 |
| Kim-Sing, C | 2 |
| Bajdik, CD | 2 |
| Trevisan, CH | 2 |
| Ludgate, CM | 1 |
| Weir, LM | 2 |
| Jackson, SM | 2 |
| Basco, VE | 2 |
| Doll, CM | 1 |
| Lam, WY | 1 |
| Rosenberg, DJ | 1 |
| Ahsan, H | 1 |
| Jacobson, JS | 1 |
| Wahid, N | 1 |
| Hagan, M | 1 |
| Rahman, MI | 1 |
| Khan, ZR | 1 |
| Pablos-Mendez, A | 1 |
| Shea, S | 1 |
| Berry, SM | 1 |
| Sibbald, B | 1 |
| Lush, DT | 1 |
| Mabro, M | 1 |
| de Gramont, A | 1 |
| Barbour, MM | 1 |
| Sharma, RA | 1 |
| Cakir, Y | 1 |
| Plummer, HK | 1 |
| Tithof, PK | 1 |
| Schuller, HM | 1 |
| Dowsett, M | 3 |
| Easty, DM | 4 |
| Neville, AM | 6 |
| Bennett, A | 1 |
| Charlier, EM | 1 |
| McDonald, AM | 1 |
| Simpson, JS | 1 |
| Stamford, IF | 1 |
| Zebro, T | 1 |
| Gazet, JC | 2 |
| Ford, HT | 1 |
| Nash, AG | 1 |
| Baker, JW | 1 |
| Powles, JT | 1 |
| Bondy, PK | 1 |
| van Aswegen, C | 1 |
| Dirksen van Schalkwyk, JC | 1 |
| Roux, LJ | 1 |
| Becker, PJ | 1 |
| Du Plessis, DJ | 1 |
| Blomgren, H | 1 |
| Rotstein, S | 1 |
| Wasserman, J | 1 |
| Petrini, B | 1 |
| Hammarström, S | 1 |
| Raub, W | 1 |
| Stoll, BA | 1 |
| Clark, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The French E3N Prospective Cohort Study (Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l'Education Nationale)[NCT03285230] | 100,000 participants (Actual) | Observational | 1990-06-15 | Active, not recruiting | |||
| Breast Cancer Active Surveillance Alternative Option, Can Aspirin Make the Difference?[NCT03491410] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2018-06-01 | Not yet recruiting | ||
| [NCT02602938] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| [NCT00000611] | Phase 3 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
36 reviews available for aspirin and Breast Cancer
| Article | Year |
|---|---|
Prophylactic aspirin intake and breast cancer risk; A systematic review and meta-analysis of observational cohort studies.
Topics: Aspirin; Breast Neoplasms; Cohort Studies; Female; Humans; Incidence; Observational Studies as Topic | 2023 |
Comment on "Prophylactic aspirin intake and breast cancer risk: A systematic review and meta-analysis of observational cohort studies".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; Female; Humans; | 2023 |
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Aspirin; Biological Products; Breast | 2020 |
Aspirin might reduce the incidence of breast cancer: An updated meta-analysis of 38 observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Humans; Incidence; Neoplasm Stag | 2020 |
Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Breast Neoplasms; Female; | 2021 |
Effect of aspirin use on survival benefits of breast cancer patients: A meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Neoplasm Recurre | 2021 |
Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Chemoprevention; Dose-Response R | 2017 |
Role of Aspirin in Breast Cancer Survival.
Topics: Aspirin; Breast Neoplasms; Female; Humans; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Risk | 2017 |
Progress in preventive therapy for cancer: a reminiscence and personal viewpoint.
Topics: Antineoplastic Agents, Hormonal; Aspirin; Breast Neoplasms; Cancer Vaccines; Clinical Trials as Topi | 2018 |
Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review.
Topics: Antineoplastic Agents, Hormonal; Aspirin; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; | 2018 |
Clinical evidence of the relationship between aspirin and breast cancer risk (review).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Clinical Trials as Topic; Cycloo | 2014 |
[Lunasin--a novel chemopreventive peptide].
Topics: Antineoplastic Agents; Antioxidants; Aspirin; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Line | 2014 |
Aspirin and NSAIDs for breast cancer chemoprevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Prognosis | 2015 |
Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review.
Topics: Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Aromatase | 2015 |
Update on breast cancer risk prediction and prevention.
Topics: Age of Onset; Aromatase Inhibitors; Aspirin; Biomarkers, Tumor; Breast Neoplasms; Diphosphonates; Fe | 2015 |
Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Cohort Stu | 2015 |
Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Neoplasm Recurre | 2015 |
Trinucleotide repeat expansions in human breast cancer-susceptibility genes: relevant targets for aspirin chemoprevention?
Topics: Aspirin; Breast Neoplasms; Chemoprevention; Female; Genes, Neoplasm; Genetic Predisposition to Disea | 2016 |
Aspirin use and risk of breast cancer: systematic review and meta-analysis of observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Observational St | 2015 |
Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Cohort Stu | 2008 |
Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Ibuprofen; Risk | 2009 |
Aspirin, salicylates, and cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Breast Neoplasms; Case-Control | 2009 |
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Digestive | 2009 |
Arterial thrombosis associated with adjuvant chemotherapy for breast cancer: a case report.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, | 2010 |
Aspirin intake may prevent metastasis in patients with triple-negative breast cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Neoplasm Metasta | 2011 |
Aspirin use and breast cancer risk: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Female; Hu | 2012 |
Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non | 2012 |
Aspirin and cancer risk: an update to 2001.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Cohort Stu | 2002 |
Aspirin and NSAIDs: effects in breast and ovarian cancers.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Femal | 2006 |
Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Controlled Clinical Trials as To | 2008 |
[Cancer of the pancreas. Epidemiology and risk factors].
Topics: Adenomatous Polyposis Coli; Age Factors; Aged; Aspirin; Breast Neoplasms; Diabetes Mellitus, Type 2; | 2007 |
Large-scale randomized evidence: large, simple trials and overviews of trials.
Topics: Aspirin; Bias; Breast Neoplasms; Cardiovascular Diseases; Effect Modifier, Epidemiologic; Female; Fi | 1993 |
Preventing heart disease and cancer. What randomized, primary-prevention studies show.
Topics: Aged; Antineoplastic Agents; Aspirin; Breast Neoplasms; Coronary Disease; Female; Heart Diseases; Hu | 1999 |
[Aspirin against cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Clinical T | 2000 |
Hormone replacement therapy should not be used as secondary prevention of coronary heart disease.
Topics: Age Factors; Aged; Aspirin; Breast Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Estrog | 2000 |
Cancer chemoprevention: a clinical reality.
Topics: Antineoplastic Agents, Hormonal; Aspirin; Breast Neoplasms; Chemoprevention; Colorectal Neoplasms; C | 2000 |
18 trials available for aspirin and Breast Cancer
| Article | Year |
|---|---|
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
Topics: Aged; Antineoplastic Agents; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Ther | 2019 |
The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomar | 2018 |
Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy.
Topics: Adult; Aged; Angiogenic Proteins; Aspirin; Blood Platelets; Breast Neoplasms; Female; Humans; Middle | 2013 |
Statins, aspirin and risk of venous thromboembolic events in breast cancer patients.
Topics: Adult; Age Factors; Aged; Aspirin; Body Mass Index; Breast Neoplasms; Case-Control Studies; Database | 2014 |
A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer.
Topics: Aspirin; Blood Platelets; Breast Neoplasms; Case-Control Studies; Clopidogrel; Drug Therapy, Combina | 2013 |
Aspirin intake and breast cancer survival - a nation-wide study using prospectively recorded data in Sweden.
Topics: Aspirin; Breast Neoplasms; Case-Control Studies; Female; Follow-Up Studies; Humans; Logistic Models; | 2014 |
Aspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Double-Blind Method; Estro | 2014 |
Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Topics: Aged; Aspirin; Breast Neoplasms; Cohort Studies; Female; Humans; Lymph Nodes; Middle Aged; Postmenop | 2016 |
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Chemotherapy, Adjuvant; Colorect | 2016 |
No effect of aspirin on mammographic density in a randomized controlled clinical trial.
Topics: Aged; Aspirin; Breast Neoplasms; Double-Blind Method; Female; Humans; Linear Models; Mammography; Mi | 2009 |
Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast; Breast Neoplasms; Case-Contro | 2011 |
A prospective study of hemoglobin A1c concentrations and risk of breast cancer in women.
Topics: Adult; Aspirin; Breast Neoplasms; Cohort Studies; Female; Glycated Hemoglobin; Humans; Placebos; Pro | 2006 |
Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality.
Topics: Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; Cyc | 2007 |
Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial.
Topics: Aged; Aspirin; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Risk | 2008 |
Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Aspirin; Blood Platelets; Breast Neoplasms; Endo | 2008 |
Use of inhibitors of prostaglandin synthesis in patients with breast cancer.
Topics: Acetaminophen; Aspirin; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Met | 1980 |
Effect of acetylsalicylic acid on radiation and cosmetic results after conservative surgery for early breast cancer: a randomized trial.
Topics: Aspirin; Breast; Breast Neoplasms; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle | 1996 |
Late cosmetic results of short fractionation for breast conservation.
Topics: Aspirin; Breast; Breast Neoplasms; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle | 1996 |
176 other studies available for aspirin and Breast Cancer
| Article | Year |
|---|---|
Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Biological Assay; Breast Neoplasms; Cell L | 2012 |
Aspirin suppresses breast cancer metastasis to lung by targeting anoikis resistance.
Topics: Animals; Anoikis; Aspirin; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lung; Lung Neoplasms; | 2022 |
The Effect of Acetylsalicylic Acid (Asa) on the Mechanical Properties of Breast Cancer Epithelial Cells.
Topics: Aspirin; Breast Neoplasms; Elastic Modulus; Epithelial Cells; Female; Humans; Microscopy, Atomic For | 2022 |
Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use.
Topics: Adult; Aspirin; Breast Density; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Hydroxyme | 2022 |
A novel role for aspirin in enhancing the reprogramming function of miR-302/367 cluster and breast tumor suppression.
Topics: Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchym | 2022 |
Design, synthesis and anticancer evaluation of novel Se-NSAID hybrid molecules: Identification of a Se-indomethacin analog as a potential therapeutic for breast cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Breast Neoplasms; Female; H | 2022 |
METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions.
Topics: Acetylation; Aspirin; Breast Neoplasms; Carcinogenesis; Female; Humans; Interleukin-6; Methyltransfe | 2022 |
Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study.
Topics: Aspirin; Breast Neoplasms; Case-Control Studies; Clopidogrel; Denmark; Dipyridamole; Female; Humans; | 2023 |
Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer.
Topics: Apoptosis; Aspirin; Breast Neoplasms; Cell Survival; Female; Humans; MCF-7 Cells; NF-kappa B; Tumor | 2023 |
Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer.
Topics: Apoptosis; Aspirin; Breast Neoplasms; Cell Survival; Female; Humans; MCF-7 Cells; NF-kappa B; Tumor | 2023 |
Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer.
Topics: Apoptosis; Aspirin; Breast Neoplasms; Cell Survival; Female; Humans; MCF-7 Cells; NF-kappa B; Tumor | 2023 |
Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer.
Topics: Apoptosis; Aspirin; Breast Neoplasms; Cell Survival; Female; Humans; MCF-7 Cells; NF-kappa B; Tumor | 2023 |
Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer.
Topics: Apoptosis; Aspirin; Breast Neoplasms; Cell Survival; Female; Humans; MCF-7 Cells; NF-kappa B; Tumor | 2023 |
Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer.
Topics: Apoptosis; Aspirin; Breast Neoplasms; Cell Survival; Female; Humans; MCF-7 Cells; NF-kappa B; Tumor | 2023 |
Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer.
Topics: Apoptosis; Aspirin; Breast Neoplasms; Cell Survival; Female; Humans; MCF-7 Cells; NF-kappa B; Tumor | 2023 |
Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer.
Topics: Apoptosis; Aspirin; Breast Neoplasms; Cell Survival; Female; Humans; MCF-7 Cells; NF-kappa B; Tumor | 2023 |
Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer.
Topics: Apoptosis; Aspirin; Breast Neoplasms; Cell Survival; Female; Humans; MCF-7 Cells; NF-kappa B; Tumor | 2023 |
Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast; Breast Neoplasms; Case-Control Studies; Cy | 2022 |
Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast; Breast Neoplasms; Case-Control Studies; Cy | 2022 |
Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast; Breast Neoplasms; Case-Control Studies; Cy | 2022 |
Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast; Breast Neoplasms; Case-Control Studies; Cy | 2022 |
Aspirin and Risk of Specific Breast Cancer Subtype in Women with Diabetes.
Topics: Aspirin; Breast Neoplasms; Diabetes Mellitus; Female; Hormones; Humans; Middle Aged; Retrospective S | 2023 |
Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women.
Topics: Aspirin; Breast Neoplasms; Case-Control Studies; Cohort Studies; Female; Humans; Male; Norway; Propo | 2023 |
Acetylsalicylic Acid Is Not Associated With Improved Clinical Outcomes After Microsurgical Breast Reconstruction.
Topics: Aspirin; Breast Neoplasms; Female; Humans; Mammaplasty; Mastectomy; Middle Aged; Necrosis; Postopera | 2023 |
Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study.
Topics: Aspirin; Breast Neoplasms; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2023 |
Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aspirin; Breast Neoplasms; Clopidogrel; Female; Humans; | 2023 |
Epigenetics and differential effects of aspirin on breast cancer survival: Opportunities for understanding human susceptibility and risk.
Topics: Aspirin; Breast Neoplasms; DNA Methylation; Epigenesis, Genetic; Epigenomics; Humans | 2019 |
Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; BRCA1 Protein; Breast Neoplasms; Caus | 2019 |
Aspirin-loaded nanoexosomes as cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; Autophagy; Breast Neoplasms; Colorectal Neoplasm | 2019 |
[Bioinformatic analysis of direct protein targets of aspirin against human breast cancer proliferation].
Topics: Aspirin; Breast Neoplasms; Cdc20 Proteins; cdc25 Phosphatases; Cell Cycle Proteins; Cell Proliferati | 2019 |
Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Aspirin; Blotting, Western; Breast Neoplasms; Cel | 2020 |
Platelets disrupt vasculogenic mimicry by cancer cells.
Topics: Animals; Apoptosis; Aspirin; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Female; Male; Mela | 2020 |
Unexpected effects of long-term treatment with acetylsalicylic acid on late phase of pulmonary metastasis in murine model of orthotopic breast cancer.
Topics: Animals; Aspirin; Breast Neoplasms; Disease Models, Animal; Disease Progression; Female; Lung Neopla | 2020 |
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspi | 2020 |
Associations of aspirin and other anti-inflammatory medications with mammographic breast density and breast cancer risk.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast; Breast Density; Breast Neoplasms; C | 2020 |
A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Apoptosis; Aspirin; Breast Neoplasms; CD24 A | 2020 |
Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Aspirin; Breast; Breast Neoplasms; Cell Different | 2020 |
Aspirin use and risk of breast cancer in African American women.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black or African American; Breast Neo | 2020 |
The improved targeting of an aspirin prodrug albumin-based nanosystem for visualizing and inhibiting lung metastasis of breast cancer.
Topics: Albumins; Aspirin; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Humans; Hydrogen Peroxide; Lung | 2020 |
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cell Cycle Proteins; Ce | 2020 |
Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; Comorbidit | 2020 |
Dual Ratiometric SERS and Photoacoustic Core-Satellite Nanoprobe for Quantitatively Visualizing Hydrogen Peroxide in Inflammation and Cancer.
Topics: Animals; Aspirin; Breast Neoplasms; Cell Line, Tumor; Female; Gold; Hydrogen Peroxide; Inflammation; | 2021 |
Antiplatelet Drug Use and Breast Cancer Risk in a Prospective Cohort of Postmenopausal Women.
Topics: Adult; Aged; Aspirin; Breast Neoplasms; Clopidogrel; Female; France; Humans; Middle Aged; Platelet A | 2021 |
Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aspirin; Blood Coagulation; Breast Neoplasms; C | 2021 |
Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Aspirin; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Line, Tumor | 2017 |
Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; California; Dose-Response | 2017 |
Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cardiovascular Dise | 2017 |
End-of-life prescribing of aspirin in patients with breast or colorectal cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Cancer Survivors; Cardiovascular Agents; Cardiov | 2019 |
Does Aspirin Decrease Risk of Specific Breast Cancer Subtype in Women with Diabetes?
Topics: Aspirin; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Risk; Risk Factors | 2017 |
[Aspirin inhibits the proliferation of breast cancer cells via inducing apoptosis and autophagy].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Autophagy; Autophagy-Related Proteins; | 2017 |
Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.
Topics: Adrenergic beta-Antagonists; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Anti-Infl | 2018 |
Use of prescription drugs and risk of postoperative red blood cell transfusion in breast cancer patients: a Danish population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2017 |
Aspirin and metformin exhibit antitumor activity in murine breast cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Ap | 2018 |
Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes.
Topics: Antineoplastic Agents; Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Dr | 2018 |
Aspirin and ibuprofen, in bulk and nanoforms: Effects on DNA damage in peripheral lymphocytes from breast cancer patients and healthy individuals.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Case-Control Studies; Comet Assay; DNA Da | 2018 |
USPSTF Recommendations: New and Updated in 2016.
Topics: Advisory Committees; Aspirin; Autism Spectrum Disorder; Breast Neoplasms; Cardiovascular Diseases; C | 2017 |
Pre-diagnostic aspirin use and mortality after breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; | 2018 |
NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Celecoxib; | 2018 |
Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells.
Topics: Amino Acid Chloromethyl Ketones; Aspirin; Blood Platelets; Breast Neoplasms; Caco-2 Cells; Calcium C | 2018 |
Potential Overestimation of Aspirin's Beneficial Effect on Breast Cancer by Study Design.
Topics: Aspirin; Breast Neoplasms; Humans; Research Design | 2018 |
From epidemiology to treatment: Aspirin's prevention of brain and breast-cancer and cardioprotection may associate with its metabolite gentisic acid.
Topics: Animals; Aspirin; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cardiotonic Agents; C | 2018 |
Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling.
Topics: Animals; Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Dise | 2018 |
The impact of aspirin use on breast cancer subtype and clinical course.
Topics: Aged; Aged, 80 and over; Aspirin; Breast; Breast Neoplasms; Cyclooxygenase Inhibitors; Disease-Free | 2018 |
Breast plasmacytoma with associated amyloidosis mimicking breast carcinoma.
Topics: Amyloidosis; Aspirin; Breast Diseases; Breast Neoplasms; Female; Humans; Immunoglobulin G; Immunoglo | 2018 |
Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Chemoprevention; Co | 2018 |
No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2018 |
Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis.
Topics: Aspirin; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Cytokines; Female; Humans; Neoplasm Me | 2019 |
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; BRCA1 Protein; Breast Neo | 2019 |
Combination of Statins and NSAIDs as a Potential Novel Addition to the Limited Anti-Breast Cancer Weaponry: A True Synergistic Model
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Breast Neoplasms; Cell Cycle Checkpoint | 2019 |
Development of a nanoamorphous exosomal delivery system as an effective biological platform for improved encapsulation of hydrophobic drugs.
Topics: Antineoplastic Agents; Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colorectal Neopla | 2019 |
Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers, Tumor; Breast Neoplasms; Carcino | 2019 |
Reduced risk of cancer among low-dose aspirin users: Data from French health care databases.
Topics: Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Databases, Factual; Dose-Response Relationship, | 2019 |
Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomark | 2013 |
Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.
Topics: Aged; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Female; Follow- | 2013 |
Low-dose aspirin use and cancer characteristics: a population-based cohort study.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; | 2013 |
Anticoagulant medication at time of needle biopsy for breast cancer in relation to risk of lymph node metastasis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biopsy, Needle; Blood Coagulation; Blood Pl | 2014 |
Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.
Topics: Acetylation; Animals; Aspirin; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Humans; M | 2014 |
Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomedical Research; Breast Neoplasms; Case-Control Studies | 2014 |
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
Topics: Animals; Apoptosis; Aromatase; Aspirin; Body Weight; Breast Neoplasms; Celecoxib; Cell Cycle; Cycloo | 2014 |
Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2014 |
Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Cohort Studies; Cyclooxygenase Inhibitors; Femal | 2014 |
Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers, Tumor; Breast; Breast Neo | 2014 |
Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Aspirin; Breast; Breast Neoplasms; Cell Prol | 2014 |
"Frankly, my dear, I don't give a damn".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomedical Research; Breast Neoplasms; Clinical Tr | 2014 |
Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Azo Compounds; | 2015 |
De Novo Post-Diagnosis Aspirin Use and Mortality in Women with Stage I-III Breast Cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Cyclooxygenas | 2015 |
Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Breast Neoplas | 2015 |
Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation.
Topics: Acetylation; Antigens, Neoplasm; Apoptosis; Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Membra | 2015 |
Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; | 2015 |
A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties.
Topics: Aspirin; Breast Neoplasms; Female; Fumarates; Gene Expression Regulation, Neoplastic; Humans; MCF-7 | 2015 |
Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Chemopreventi | 2016 |
Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.
Topics: Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Asp | 2016 |
Aspirin Breaks the Crosstalk between 3T3-L1 Adipocytes and 4T1 Breast Cancer Cells by Regulating Cytokine Production.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Brea | 2016 |
Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFκB-IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells.
Topics: Aspirin; Breast Neoplasms; Cell Line, Tumor; Cohort Studies; Female; Humans; Interleukin-6; Microsco | 2016 |
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Topics: Aspirin; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Cytostatic Ag | 2016 |
Do postoperative NSAIDs improve breast cancer outcomes? A Best Evidence Topic.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Middle Aged; Pos | 2016 |
Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2016 |
Mutations in PIK3CA Sensitize Breast Cancer Cells to Physiologic Levels of Aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Class I Phosphatidylinositol 3-K | 2016 |
Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women's Health Study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; | 2016 |
Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neo | 2017 |
Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Breast Neop | 2017 |
Low-dose aspirin use and survival in breast cancer patients: A nationwide cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Cohort Studies; Comorbidity; Cyclooxygenase Inhi | 2017 |
Aspirin use is associated with lower mammographic density in a large screening cohort.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Breast Density; Breast Neoplasms; Dose-Response | 2017 |
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells.
Topics: Aspirin; Breast Neoplasms; Cell Line, Tumor; Fumarates; Gene Expression Regulation; Humans; Neoplast | 2017 |
Association between aspirin use triple negative breast cancer: More benefit is expected.
Topics: Aspirin; Breast Neoplasms; Cohort Studies; Humans; Receptor, ErbB-2; Receptors, Estrogen; Receptors, | 2017 |
Low-dose aspirin use and survival in breast cancer patients: A nationwide cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; Humans | 2017 |
Aspisol inhibits tumor growth and induces apoptosis in breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; bcl-2-Associated X Protein; Blotting, Western; B | 2008 |
Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Hu | 2009 |
Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Aspirin; bcl-2-Associated X Protein; Breast Neoplasms | 2009 |
Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling.
Topics: Anticarcinogenic Agents; Aspirin; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; beta | 2009 |
Aspirin intake and survival after breast cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Breast Neoplasms; | 2010 |
Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoco | 2010 |
I've been reading that aspirin can help prevent breast cancer. What can you tell me about this?
Topics: Aspirin; Biomedical Research; Breast Neoplasms; Female; Humans; Treatment Outcome | 2010 |
Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studie | 2010 |
USPSTF recommendations you may have missed amid the breast cancer controversy.
Topics: Adolescent; Age Factors; Aspirin; Breast Neoplasms; Breast Self-Examination; Child; Depression; Depr | 2010 |
Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; Female; Fo | 2011 |
Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected].
Topics: Adult; Aged; Aspirin; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm R | 2010 |
Can taking a daily aspirin reduce my chance of breast cancer recurrence?
Topics: Aspirin; Breast Neoplasms; Chemoprevention; Drug Administration Schedule; Female; Health Knowledge, | 2010 |
Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers, Tumor; Breast Neoplasms; | 2011 |
Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis.
Topics: Adenosine Diphosphate; Angiogenesis Modulating Agents; Aspirin; Blood Platelets; Breast Neoplasms; C | 2011 |
COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin.
Topics: Adult; Antineoplastic Agents; Aspirin; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breas | 2011 |
Regular aspirin use and breast cancer risk in US Black women.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black or African American; B | 2011 |
The association between mammographic density measures and aspirin or other NSAID use.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cross-Sectional Stu | 2012 |
COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Berberine; Biomarkers, Tumor; Breast Neoplasms; Carcinoma | 2012 |
Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Prolife | 2012 |
Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Topics: Aspirin; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Survival; Chemokine CXCL10; Chemokine C | 2012 |
Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; M | 2012 |
Breast cancer risk reduction: no pain, no gain?
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; P | 2012 |
Angiotensin-converting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer: a nationwide case-control study.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ste | 2012 |
Migraine and subsequent risk of breast cancer: a prospective cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Carcinoma; Chemoprevention; Cohort Studies; Doub | 2013 |
Direct regulation of caspase‑3 by the transcription factor AP‑2α is involved in aspirin‑induced apoptosis in MDA‑MB‑453 breast cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Breast Neoplasms; Caspase 3; Cell Line, | 2013 |
Synergistic effects of exemestane and aspirin on MCF-7 human breast cancer cells.
Topics: Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; | 2012 |
Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort S | 2002 |
Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells.
Topics: Arachidonic Acid; Aspirin; Breast Neoplasms; Cell Membrane; Cell Movement; Cholesterol; Chromatograp | 2003 |
By the way, doctor. I recently read that anti-inflammatory drugs reduce the risk of breast cancer. Is this true? Can you tell me anything about this?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cyclooxygenase Inhibitors; Femal | 2003 |
Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studie | 2003 |
COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells.
Topics: Apoptosis; Aspirin; Breast Neoplasms; CDC2-CDC28 Kinases; Cell Division; Cell Line, Tumor; Cell Surv | 2004 |
Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; As | 2004 |
Aspirin and breast cancer prevention: the estrogen connection.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Receptors | 2004 |
Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis.
Topics: Adenomatous Polyposis Coli; Apoptosis; Aspirin; beta Catenin; Breast Neoplasms; Cell Nucleus; Colore | 2004 |
Risk of breast cancer among users of aspirin and other anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studie | 2004 |
Aspirin and breast cancer prevention--a link to ER status.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Breast Neoplasms; Cycloox | 2004 |
Association of aspirin use and hormone receptor status with breast cancer risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Breast Neoplasms; Humans | 2004 |
Association of aspirin use and hormone receptor status with breast cancer risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Breast Neoplasms; Humans; | 2004 |
Study finds aspirin may prevent certain breast cancers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Breast Neoplasms; Female; | 2004 |
Aspirin may protect against breast cancer. But tamoxifen and mastectomy are still the only proven preventatives, though other approaches are under study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; A | 2004 |
Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2005 |
Anti-inflammatory drugs and malignancy: can an aspirin a day keep cancer at bay?
Topics: Aspirin; Breast Neoplasms; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Female; Humans; Male; Ne | 2005 |
Association of regular aspirin use and breast cancer risk.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studie | 2005 |
Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bre | 2005 |
Clinical trials point to complexities of chemoprevention for cancer.
Topics: Aspirin; Breast Neoplasms; Clinical Trials as Topic; Diet; Dihydrotestosterone; Female; Finasteride; | 2005 |
Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer.
Topics: Acetaminophen; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Ag | 2005 |
The role of insulin dependent NO synthesis in the impaired production of maspin in human breast cancer.
Topics: Aged; Alprostadil; Aspirin; Binding, Competitive; Breast Neoplasms; Cyclic GMP; Dose-Response Relati | 2006 |
Restoration by aspirin of impaired plasma maspin level in human breast cancer.
Topics: Aged; Aspirin; Breast Neoplasms; Female; Genes, Tumor Suppressor; Humans; Middle Aged; Nitric Oxide; | 2006 |
Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk.
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; C | 2006 |
NSAIDs and breast cancer recurrence in a prospective cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; California; Chemopreventio | 2007 |
IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers, Tumor; Breast Neoplasms; Case-Control | 2007 |
Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2007 |
Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; Cyc | 2007 |
Central venous catheter-related thrombosis in cancer patients: what we know and what we need to know.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2008 |
Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; Denmark; F | 2008 |
Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Cycl | 2008 |
Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2008 |
[A method of determining the antiaggregation activity of the vascular wall in man].
Topics: Arteriosclerosis; Aspirin; Blood Vessels; Breast Neoplasms; Endothelium; Epoprostenol; Humans; Plate | 1983 |
A functional cyclooxygenase enzyme is not required for mediation of the pleiotropic effects of human alpha or beta interferon.
Topics: Aspirin; Breast Neoplasms; Cell Line; Female; Fibroblasts; Humans; Indomethacin; Interferon Type I; | 1983 |
Human benign breast disease: relationships between prostaglandin E2, steroid hormones, and thermographic effects of the inhibitors of PG biosynthesis.
Topics: Adult; Aspirin; Breast Diseases; Breast Neoplasms; Corpus Luteum; Estradiol; Female; Humans; Indomet | 1980 |
[Thromboembolic accidents in postmenopausal patients with adjuvant treatment by tamoxifen. Frequency, risk factors and prevention possibilities].
Topics: Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Hemostasis; Huma | 1995 |
A broad anticancer effect of aspirin?
Topics: Aspirin; Breast Neoplasms; Colonic Neoplasms; Confounding Factors, Epidemiologic; Female; Humans; Lu | 1994 |
Aspirin use and lung, colon, and breast cancer incidence in a prospective study.
Topics: Adult; Aged; Aspirin; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; Confidence Intervals; | 1994 |
Aspirin and breast cancer: no surprises yet.
Topics: Animals; Antineoplastic Agents; Aspirin; Breast Neoplasms; Drug Utilization; Female; Humans; Mammary | 1996 |
Prospective study of regular aspirin use and the risk of breast cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Breast Neoplasms; | 1996 |
Nonsteroidal antiinflammatory drugs and breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 1996 |
Association between coronary heart disease and cancers of the breast, prostate, and colon.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Colo | 1998 |
Understanding and testing for heterogeneity across 2 x 2 tables: application to meta-analysis.
Topics: Antineoplastic Agents, Hormonal; Aspirin; Bayes Theorem; Breast Neoplasms; Humans; Meta-Analysis as | 1998 |
Breast cancer conference marred by questionable presentations, critics charge.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Environment; Female; Humans; Pre | 1999 |
Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Arachidonate 5-Lipoxygenase; Arachidonic Acid | 2002 |
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin.
Topics: Animals; Aspirin; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Cultur | 1976 |
Prostaglandins and breast cancer.
Topics: Adolescent; Adult; Aged; Aspirin; Bone Neoplasms; Breast Neoplasms; Female; Humans; In Vitro Techniq | 1977 |
Agents affecting osteolysis in patients with breast cancer.
Topics: Anti-Inflammatory Agents; Aspirin; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcitonin; Fe | 1979 |
In vitro osteolysis by human breast tumours.
Topics: Aspirin; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Female; Humans; In Vitro Techni | 1977 |
Human breast tumour-induced osteolysis and prostaglandins.
Topics: Aspirin; Bone Resorption; Breast Neoplasms; Female; Humans; Indomethacin; Osteolysis; Prostaglandins | 1976 |
Failure of indomethacin to reduce hypercalcemia in patients with breast cancer.
Topics: Aspirin; Bone Neoplasms; Breast Neoplasms; Calcium; Creatinine; Female; Humans; Hydroxyproline; Hype | 1976 |
A novel study on the effect of acetylsalicylic acid on the binding capacity of estrogen receptors from MCF-7 cells.
Topics: Antibodies, Monoclonal; Aspirin; Binding Sites; Breast Neoplasms; Estradiol; Humans; Immunoenzyme Te | 1992 |
In vitro capacity of various cyclooxygenase inhibitors to revert immune suppression caused by radiation therapy for breast cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cyclooxygenase Inhi | 1990 |
From the National Institutes of Health.
Topics: Aspirin; Breast Neoplasms; Female; Fetal Diseases; Heart Defects, Congenital; Humans; Immunotherapy; | 1990 |
Indomethacin in breast cancer.
Topics: Aged; Animals; Aspirin; Breast Neoplasms; Female; Humans; Indomethacin; Mice; Rats | 1973 |
The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer.
Topics: Animals; Aspirin; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Calciu | 1973 |